Author: "Pascal de Groote" / Search Limiters: Full Text - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Pascal de Groote"' showing total 108 results

Start Over Author "Pascal de Groote" Search Limiters Full Text

108 results on '"Pascal de Groote"'

1. French guidelines for the etiological workup of eosinophilia and the management of hypereosinophilic syndromes

Author: Matthieu Groh, Julien Rohmer, Nicolas Etienne, Wadih Abou Chahla, Antoine Baudet, Aurélie Chan Hew Wai, Cécile Chenivesse, Irena Clisson Rusek, Vincent Cottin, Matthieu Decamp, Pascal De Groote, Fanny Delahousse, Nicolas Duployez, Stanislas Faguer, Frédéric Gottrand, Florent Huang, Thierry Leblanc, Antoine Magnan, Thierry Martin, Geoffrey Mortuaire, Antoine Néel, Luc Paris, Arnaud Petit, Julien Rossignol, Nicolas Schleinitz, Juliette Soret-Dulphy, Delphine Staumont-Salle, Benjamin Terrier, Louis Terriou, Jean-François Viallard, Guillaume Lefèvre, and Jean-Emmanuel Kahn
Subjects: Hypereosinophilia, Hypereosinophilic syndromes, Recommendation, Management, Medicine
Abstract: Abstract Eosinophilic-related clinical manifestations are protean and the underlying conditions underpinning eosinophilia are highly diverse. The etiological workup of unexplained eosinophilia/hypereosinophilia can be challenging, and can lead sometimes to extensive, inappropriate, costly and/or invasive investigations. To date, guidelines for the etiological workup and management of eosinophilia are mainly issued by hematologists, and thus mostly cover the scope of clonal hypereosinophilic syndromes (HES). Here, thanks to an extensive literature review, and thanks to the joint work of a large panel of experts involving physicians from both adult and pediatric medicine and from various subspecialties (as well as a representative of a patients’ association representative), we provide recommendations for both the step-by step diagnostic workup of eosinophilia (whether unexplained or within specific contexts) as well as the management and follow-up of the full spectrum of eosinophilic disorders (including clonal, reactive, lymphocytic and idiopathic HES, as well as single-organ diseases). Didactic prescription summaries intended to facilitate the prescription of eosinophil-targeted drugs are also provided, as are practical diagnostic and therapeutic algorithms. Lastly, this set of recommendations also includes a summary intended for general practitioners, as well as an overview of the therapeutic patient education program set up by the French reference center for HES. Further updates will be mandatory as new validated information emerges.
Published: 2023
Full Text: View/download PDF

2. Mild pulmonary hemodynamic alterations in patients with systemic sclerosis: relevance of the new 2022 ESC/ERS definition of pulmonary hypertension and impact on mortality

Author: Sébastien Puigrenier, Jonathan Giovannelli, Nicolas Lamblin, Pascal De Groote, Marie Fertin, Jean-François Bervar, Antoine Lamer, Jean-Louis Edmé, Marie-Hélène Balquet, Vincent Sobanski, David Launay, Éric Hachulla, and Sébastien Sanges
Subjects: Systemic sclerosis, Pulmonary hypertension, Pulmonary arterial hypertension, Pulmonary vascular resistance, Diagnostic criteria, Mortality, Diseases of the respiratory system, RC705-779
Abstract: Abstract Background and objective The definition of pre-capillary pulmonary hypertension (PH) has been modified, with lowering of the mean pulmonary arterial pressure (mPAP) threshold from 25 to 20 mmHg and addition of a mandatory criterion of pulmonary vascular resistance (PVR) ≥ 2 Wood units (WU). Our objectives were: 1/ to estimate the proportion of patients reclassified as having pre-capillary PH when using the new 2022 ESC/ERS hemodynamic criteria (i.e. mPAP 21-24 mmHg and PVR ≥ 2 WU), and to describe their clinical characteristics and outcome; and 2/ to study the relationship between PVR and survival in patients with mPAP > 20 mmHg. Methods We retrospectively analyzed consecutive SSc patients included in our National Reference Center for a first right-heart catheterization between 2003 and 2018. The association between survival and PVR was studied using smoothing splines. Results We included 126 SSc patients with mPAP > 20 mmHg. Among them, 16 (13%) had a baseline mPAP value between 21 and 24 mmHg and PVR ≥ 2 mmHg and were reclassified as pre-capillary PH; 10 of which (62%) raised their mPAP ≥ 25 mmHg during follow-up. In patients with mPAP > 20 mmHg, we observed a linear relation between PVR and mortality for values 25 mmHg, with a possibly less severe disease.
Published: 2022
Full Text: View/download PDF

3. French recommendations for the management of systemic sclerosis

Author: Eric Hachulla, Christian Agard, Yannick Allanore, Jerome Avouac, Brigitte Bader-Meunier, Alexandre Belot, Alice Berezne, Anne-Sophie Bouthors, Geraldine Condette-Wojtasik, Joël Constans, Pascal De Groote, Elisabeth Diot, Florence Dumas, Patrick Jego, Francisca Joly, David Launay, Veronique Le Guern, Janine-Sophie Le Quintrec, Geraldine Lescaille, Christophe Meune, Bruno Moulin, Christelle Nguyen, Nadine Omeish, Frederic Pene, Marie-Aleth Richard, Juliette Rochefort, Alexandra Roren, Olivier Sitbon, Vincent Sobanski, Marie-Elise Truchetet, Luc Mouthon, and Collaborators
Subjects: Systemic sclerosis, Recommendations, Treatment, Medicine
Abstract: Abstract Systemic sclerosis (SSc) is a generalized disease of the connective tissue, arterioles, and microvessels, characterized by the appearance of fibrosis and vascular obliteration. There are two main phenotypical forms of SSc: a diffuse cutaneous form that extends towards the proximal region of the limbs and/or torso, and a limited cutaneous form where the cutaneous sclerosis only affects the extremities of the limbs (without passing beyond the elbows and knees). There also exists in less than 10% of cases forms that never involve the skin. This is called SSc sine scleroderma. The prognosis depends essentially on the occurrence of visceral damage and more particularly interstitial lung disease (which is sometimes severe), pulmonary arterial hypertension, or primary cardiac damage, which represent the three commonest causes of mortality in SSc. Another type of involvement with poor prognosis, scleroderma renal crisis, is rare (less than 5% of cases). Cutaneous extension is also an important parameter, with the diffuse cutaneous forms having less favorable prognosis.
Published: 2021
Full Text: View/download PDF

4. Prescription, Compliance, and Burden Associated with Salt-Restricted Diets in Heart Failure Patients: Results from the French National OFICSel Observatory

Author: Thibaud Damy, Véronique Benedyga, Théo Pezel, Emmanuelle Berthelot, Jacques Gauthier, Gilbert Habib, Marie-Christine Iliou, Jean-François Aupetit, Guillaume Baudry, Pascal De Groote, Damien Logeart, Laure Chaufourier, Vlad Ciobotaru, Françoise Pousset, Florence Beauvais, Fabrice Bauer, Florian Zores, Olivier Lairez, Kevin Richard, Luc Hittinger, Emmanuel Teiger, Charles Taieb, and Etienne Audureau
Subjects: heart failure, patient education, restricted diets, salt diet, OFICSel observatory, patient burden, Nutrition. Foods and food supply, TX341-641
Abstract: (1) Background: There is much debate about the use of salt-restricted diet for managing heart failure (HF). Dietary guidelines are inconsistent and lack evidence. (2) Method: The OFICSel observatory collected data about adults hospitalised for HF. The data, collected using study-specific surveys, were used to describe HF management, including diets, from the cardiologists’ and patients’ perspectives. Cardiologists provided the patients’ clinical, biological, echocardiography, and treatment data, while the patients provided dietary, medical history, sociodemographic, morphometric, quality of life, and burden data (burden scale in restricted diets (BIRD) questionnaire). The differences between the diet recommended by the cardiologist, understood by the patient, and the estimated salt intake (by the patient) and diet burden were assessed. (3) Results: Between March and June 2017, 300 cardiologists enrolled 2822 patients. Most patients (90%) were recommended diets with
Published: 2022
Full Text: View/download PDF

5. Factors associated with the 6-minute walk distance in patients with systemic sclerosis

Author: Sébastien Sanges, Jonathan Giovannelli, Vincent Sobanski, Sandrine Morell-Dubois, Hélène Maillard, Marc Lambert, Céline Podevin, Nicolas Lamblin, Pascal De Groote, Jean-François Bervar, Thierry Perez, Régis Matran, Martine Rémy-Jardin, Pierre-Yves Hatron, Éric Hachulla, and David Launay
Subjects: Systemic sclerosis, 6-minute walk test, Chronotropic incompetence, Exercise tolerance, Interstitial lung disease, Pulmonary hypertension, Diseases of the musculoskeletal system, RC925-935
Abstract: Abstract Background There is an ongoing debate regarding the relevance of the 6-minute walking distance (6MWD) in systemic sclerosis (SSc) assessment, widely used as a usual test in these patients as well as an outcome measure in clinical trials. In this work, we aimed to assess the associations between the 6MWD and various disease parameters in patients with SSc. Methods Consecutive patients followed in our SSc National Reference Centre were included in this cross-sectional study if they fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc. Data were systematically collected during a comprehensive standardized evaluation that included a 6-minute walk test, clinical assessment, biological results, pulmonary function tests, transthoracic echocardiography, composite scores (European Scleroderma Study Group Activity Index, Medsger severity score, Health Assessment Questionnaire–Disability Index (HAQ-DI)) and treatments. Associations of the 6MWD with various disease parameters were assessed by linear regression in univariate and multivariate analyses. Results The study population comprised 298 patients (females 81%; mean age 58.2 ± 13.3 years; limited cutaneous SSc 82%; interstitial lung disease (ILD) 42%; pulmonary arterial hypertension (PAH) 6%). The 6MWD was significantly and independently associated with gender, age, body mass index, baseline heart rate (HR), HR variation during the test, PAH, history of arterial thrombosis and C-reactive protein levels, as well as with the HAQ-DI score in a sensitivity analysis. Muscle involvement, joint involvement and ILD were not independently associated with the 6MWD. Conclusions During SSc, the 6MWD is independently associated with initial HR and HR variation; with PAH but not ILD, suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation; and with global markers of disease activity and patient disability. These results give clinicians further insight into how to interpret the 6MWD in the context of SSc.
Published: 2017
Full Text: View/download PDF

6. Recurrent suspected myocarditis combined with infrahisian conduction disturbances revealing a desminopathy

Author: Stéphane Boulé, MD, Pascale Richard, MD, PhD, Pascal de Groote, MD, PhD, Florence Renaud, MD, and Philippe Charron, MD, PhD, FESC
Subjects: Desminopathy, Myocarditis, Cardiomyopathy, Atrioventricular block, Pacemaker, Desmin, Purkinje, Diseases of the circulatory (Cardiovascular) system, RC666-701
Published: 2015
Full Text: View/download PDF

7. Long-term prognostic impact of left ventricular remodeling after a first myocardial infarction in modern clinical practice.

Author: Christophe Bauters, Emilie Dubois, Sina Porouchani, Eric Saloux, Marie Fertin, Pascal de Groote, Nicolas Lamblin, and Florence Pinet
Subjects: Medicine, Science
Abstract: The association of left ventricular remodeling (LVR) after myocardial infarction (MI) with the subsequent risk of heart failure (HF) and death has not been studied in patients receiving optimal secondary prevention.We performed a long-term clinical follow-up of patients included in 2 prospective multicentric studies on LVR after first anterior MI. At 1-year echocardiography, LVR (≥20% increase in end-diastolic volume from baseline to 1 year) occurred in 67/215 (31%) patients in cohort 1 and in 87/226 (38%) patients in cohort 2. The prescription rate of secondary prevention medications was very high (ß-blockers at 1 year: 90% and 95% for cohorts 1 and 2, respectively; angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACE-I/ARB) at 1 year: 93% and 97% for cohorts 1 and 2, respectively). Median clinical follow-up after LVR assessment was 11.0 years in cohort 1 and 7.8 years in cohort 2. In both cohorts, LVR patients had a progressive increase in the risk of cardiovascular death or hospitalization for HF (p = 0.0007 in cohort 1 and 0.009 in cohort 2) with unadjusted hazard ratios of 2.52 [1.45-4.36] and 2.52 [1.23-5.17], respectively. Similar results were obtained when cardiovascular death was considered as an isolated endpoint. After adjustement on baseline characteristics including ejection fraction, the association with the composite endpoint was unchanged.In a context of a modern therapeutic management with a large prescription of evidence-based medications, LVR remains independently associated with HF and cardiovascular death at long-term follow-up after MI.
Published: 2017
Full Text: View/download PDF

8. Bisoprolol in the treatment of chronic heart failure

Author: Pascal de Groote, Pierre-Vladimir Ennezat, and Fréderic Mouquet
Subjects: Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract: Pascal de Groote1, Pierre-Vladimir Ennezat2, Fréderic Mouquet11Service de Cardiologie C, 2Service des soins intensifs cardiologiques, Hôpital Cardiologique, Centre Hospitalier Régional et Universitaire de Lille, FranceAbstract: Bisoprolol fumarate is a highly selective beta-1 receptor blocker. Bisoprolol has been extensively studied in three large mortality trials in stable chronic heart failure (CHF) patients. The CIBIS trial enrolled 641 patients and demonstrated the good tolerability of bisoprolol in a large CHF population, without evidence for any harmful effect. The CIBIS-II study was the first large randomized, double-blind, placebo-controlled study demonstrating in 2647 patients a dramatic reduction in mortality with a beta-blocking agent in CHF patients. CIBIS-III demonstrated in 1010 patients the equivalence of 2 different therapeutic strategies in de novo CHF patients. There was no difference in morbidity and mortality between sub-groups of patients receiving first bisoprolol or enalapril. These three trials also demonstrated the good tolerability of bisoprolol fumarate. Other studies were either limited in number of patients or not randomized. However, these studies confirmed the good tolerability of bisoprolol in CHF patients, even in elderly population. Bisoprolol fumarate is a selective beta-1 receptor blocker that significantly reduced morbidity and mortality in stable CHF patients. Bisoprolol is well tolerated with few significant side effects in different large trials.Keywords: bisoprolol, chronic heart failure, beta-blocker
Published: 2007

9. Multimarker proteomic profiling for the prediction of cardiovascular mortality in patients with chronic heart failure.

Author: Gilles Lemesle, Fleur Maury, Olivia Beseme, Lionel Ovart, Philippe Amouyel, Nicolas Lamblin, Pascal de Groote, Christophe Bauters, and Florence Pinet
Subjects: Medicine, Science
Abstract: Risk stratification of patients with systolic chronic heart failure (HF) is critical to better identify those who may benefit from invasive therapeutic strategies such as cardiac transplantation. Proteomics has been used to provide prognostic information in various diseases. Our aim was to investigate the potential value of plasma proteomic profiling for risk stratification in HF. A proteomic profiling using surface enhanced laser desorption ionization - time of flight - mass spectrometry was performed in a case/control discovery population of 198 patients with systolic HF (left ventricular ejection fraction
Published: 2015
Full Text: View/download PDF

10. Relevance of partitioning DLCO to detect pulmonary hypertension in systemic sclerosis.

Author: Nadia Sivova, David Launay, Lidwine Wémeau-Stervinou, Pascal De Groote, Martine Remy-Jardin, Guillaume Denis, Marc Lambert, Nicolas Lamblin, Sandrine Morell-Dubois, Marie Fertin, Guillaume Lefevre, Vincent Sobanski, Olivier Le Rouzic, Pierre-Yves Hatron, Benoit Wallaert, Eric Hachulla, and Thierry Perez
Subjects: Medicine, Science
Abstract: We investigated whether partitioning DLCO into membrane conductance for CO (DmCO) and pulmonary capillary blood volume (Vcap) was helpful in suspecting precapillary pulmonary (arterial) hypertension (P(A)H) in systemic sclerosis (SSc) patients with or without interstitial lung disease (ILD). We included 63 SSc patients with isolated PAH (n=6), isolated ILD (n=19), association of both (n=12) or without PAH and ILD (n=26). Partitioning of DLCO was performed by the combined DLNO/DLCO method. DLCO, DmCO and Vcap were equally reduced in patients with isolated PAH and patients with isolated ILD but Vcap/alveolar volume (VA) ratio was significantly lower in the isolated PAH group. In patients without ILD, DLCO, DmCO, Vcap and Vcap/VA ratio were reduced in patients with isolated PAH when compared to patients without PAH and both Vcap/VA and DLCO had the highest AUC to detect PAH. In patients with ILD, Vcap had the highest AUC and performed better than DLCO to detect PH in this subgroup. In conclusion, Vcap/VA was lower in PAH than in ILD in SSC whereas DLCO was not different. Vcap/VA ratio and DLCO had similar high performance to detect PAH in patients without ILD. Vcap had better AUC than DLCO, DmCO and FVC/DLCO ratio to detect PH in SSC patients with ILD. These results suggest that partitioning of DLCO might be of interest to detect P(A)H in SSC patients with or without ILD.
Published: 2013
Full Text: View/download PDF

11. Serum and Pulmonary Expression Profiles of the Activin Signaling System in Pulmonary Arterial Hypertension

Author: Christophe Guignabert, Laurent Savale, Athénaïs Boucly, Raphaël Thuillet, Ly Tu, Mina Ottaviani, Christopher J. Rhodes, Pascal De Groote, Grégoire Prévot, Emmanuel Bergot, Arnaud Bourdin, Luke S. Howard, Elie Fadel, Antoine Beurnier, Anne Roche, Mitja Jevnikar, Xavier Jaïs, David Montani, Martin R. Wilkins, Olivier Sitbon, and Marc Humbert
Subjects: Physiology (medical), Cardiology and Cardiovascular Medicine
Abstract: BACKGROUND: Activins are novel therapeutic targets in pulmonary arterial hypertension (PAH). We therefore studied whether key members of the activin pathway could be used as PAH biomarkers. METHODS: Serum levels of activin A, activin B, α-subunit of inhibin A and B proteins, and the antagonists follistatin and follistatin-like 3 (FSTL3) were measured in controls and in patients with newly diagnosed idiopathic, heritable, or anorexigen-associated PAH (n=80) at baseline and 3 to 4 months after treatment initiation. The primary outcome was death or lung transplantation. Expression patterns of the inhibin subunits, follistatin, FSTL3, Bambi, Cripto, and the activin receptors type I (ALK), type II (ACTRII), and betaglycan were analyzed in PAH and control lung tissues. RESULTS: Death or lung transplantation occurred in 26 of 80 patients (32.5%) over a median follow-up of 69 (interquartile range, 50–81) months. Both baseline (hazard ratio, 1.001 [95% CI, 1.000–1.001]; P =0.037 and 1.263 [95% CI, 1.049–1.520]; P =0.014, respectively) and follow-up (hazard ratio, 1.003 [95% CI, 1.001–1.005]; P =0.001 and 1.365 [95% CI, 1.185–1.573]; P P =0.009) and 0.17 (95% CI, 0.06–0.45; P P =0.019) and 0.27 (95% CI, 0.09–0.78, P =0.015), respectively. Prognostic values of activin A and FSTL3 were confirmed in an independent external validation cohort. Histological analyses showed a nuclear accumulation of the phosphorylated form of Smad2/3, higher immunoreactivities for ACTRIIB, ALK2, ALK4, ALK5, ALK7, Cripto, and FSTL3 in vascular endothelial and smooth muscle layers, and lower immunostaining for inhibin-α and follistatin. CONCLUSIONS: These findings offer new insights into the activin signaling system in PAH and show that activin A and FSTL3 are prognostic biomarkers for PAH.
Published: 2023

12. Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension

Author: Vincent Cottin, David Montani, Jérémie Pichon, Martine Reynaud-Gaubert, Xavier Jaïs, Pascal Magro, Gérald Simonneau, Florence Parent, Fabrice Bauer, Marianne Riou, Laurent Bertoletti, Pamela Moceri, Ari Chaouat, Andrei Seferian, Antoine Beurnier, Sébastien Renard, Pierre Mauran, Delphine Horeau-Langlard, Pascal de Groote, Laurent Savale, Mitja Jevnikar, Sophie Bulifon, Pascal Roblot, Hélène Bouvaist, Yuanchao Feng, Patrice Poubeau, Sylvain Palat, Zhiying Liang, Emmanuel Bergot, François Picard, Etienne-Marie Jutant, C. Chabanne, Olivier Sitbon, Athénaïs Boucly, Grégoire Prévot, Jean-François Mornex, Cécile Tromeur, Marc Humbert, Bruno Degano, Claire Dauphin, Arnaud Bourdin, Olivier Sanchez, Nicolas Favrolt, Jason Weatherald, Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Centre chirurgical Marie Lannelongue-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Normandie Université (NU), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Université de Caen Normandie (UNICAEN), Biologie intégrative du tissu osseux, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire [Grenoble] (CHU), Laboratoire Traitement du Signal et de l'Image (LTSI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), CHU Pontchaillou [Rennes], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Infections Virales et Pathologie Comparée - UMR 754 (IVPC), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hospices Civils de Lyon (HCL), CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), University of Calgary, Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Nord Laennec [CHU Nantes], CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Universitaire de Reims (CHU Reims), American Memorial Hospital (Hôpital des enfants) [Reims], Centre Hospitalier Universitaire de Nice (CHU Nice), Université Côte d'Azur (UCA), Hôpital Dupuytren [CHU Limoges], Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Université de Bordeaux (UB), Centre Hospitalier Universitaire de La Réunion (CHU La Réunion), Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Hôpital de la Timone [CHU - APHM] (TIMONE), Assistance Publique - Hôpitaux de Marseille (APHM), Aix Marseille Université (AMU), Nouvel Hôpital Civil de Strasbourg, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, Centre Chirurgical Marie Lannelongue (CCML)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biologie Intégrative du Tissu Osseux (LBTO), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), École Pratique des Hautes Études (EPHE), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre chirurgical Marie Lannelongue, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), and MORNET, Dominique
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, business.industry, [SDV]Life Sciences [q-bio], Critical Care and Intensive Care Medicine, medicine.disease, survival, Pulmonary hypertension, 3. Good health, [SDV] Life Sciences [q-bio], pulmonary arterial hypertension, Internal medicine, pulmonary hypertension, Long term survival, therapeutics, Cardiology, Medicine, Initial treatment, business
Abstract: International audience; Rationale: The relationship between the initial treatment strategy and survival in pulmonary arterial hypertension (PAH) remains uncertain. Objectives: To evaluate the long-term survival of patients with PAH categorized according to the initial treatment strategy. Methods: A retrospective analysis of incident patients with idiopathic, heritable, or anorexigen-induced PAH enrolled in the French Pulmonary Hypertension Registry (January 2006 to December 2018) was conducted. Survival was assessed according to the initial strategy: monotherapy, dual therapy, or triple-combination therapy (two oral medications and a parenteral prostacyclin). Measurements and Main Results: Among 1,611 enrolled patients, 984 were initiated on monotherapy, 551 were initiated on dual therapy, and 76 were initiated on triple therapy. The triple-combination group was younger and had fewer comorbidities but had a higher mortality risk. The survival rate was higher with the use of triple therapy (91% at 5 yr) as compared with dual therapy or monotherapy (both 61% at 5 yr) (P < 0.001). Propensity score matching of age, sex, and pulmonary vascular resistance also showed significant differences between triple therapy and dual therapy (10-yr survival, 85% vs. 65%). In high-risk patients (n = 243), the survival rate was higher with triple therapy than with monotherapy or dual therapy, whereas there was no difference between monotherapy and double therapy. In intermediate-risk patients (n = 1,134), survival improved with an increasing number of therapies. In multivariable Cox regression, triple therapy was independently associated with a lower risk of death (hazard ratio, 0.29; 95% confidence interval, 0.11-0.80; P = 0.017). Among the 148 patients initiated on a parenteral prostacyclin, those on triple therapy had a higher survival rate than those on monotherapy or dual therapy. Conclusions: Initial triple-combination therapy that includes parenteral prostacyclin seems to be associated with a higher survival rate in PAH, particularly in the youngest high-risk patients.
Published: 2021

13. Feasibility and accuracy of linking a heart failure registry to the national claims database using indirect identifiers

Author: Damien Logeart, Thibaud Damy, Maxime Doublet, Muriel Salvat, Christophe Tribouilloy, Fabrice Bauer, Jean-Christophe Eicher, François Picard, Gérald Roul, Jean-Noël Trochu, Pascal De Groote, Nicolas Bihry, Emmanuelle Berthelot, Guillaume Jondeau, Marie-France Seronde, François Roubille, and Richard Isnard
Subjects: General Medicine, Cardiology and Cardiovascular Medicine
Abstract: Heart failure (HF) registries include rich data on patient inclusion characteristics, but follow-up information is often incomplete. Medicoadministrative databases may provide less clinical information than registries, e.g. on left ventricular ejection fraction (LVEF), but long-term data are exhaustive and reliable. The combination of the two types of database is therefore appealing, but the feasibility and accuracy of such linking are largely unexplored.To assess the feasibility and accuracy of linking an HF registry (FRESH; FREnch Survey on Heart Failure) with the French National Healthcare System database (SNDS).A probabilistic algorithm was developed to link and match patient data included in the FRESH HF registry with anonymized records from the SNDS, which include: hospitalizations and diagnostic codes; all care-related reimbursements by national health system; and deaths. Consistency was assessed between deaths recorded in the registry and in the SNDS. A comparison between the two databases was carried out on several identifiable clinical characteristics (history of HF hospitalization, diabetes, atrial fibrillation, chronic bronchopneumopathy, severe renal failure and stroke) and on events during 1-year follow-up after inclusion.Of 2719 patients included in the FRESH registry (1049 during decompensation; 1670 during outpatient follow-up), 1885 could be matched with a high accuracy of 94.3% for deaths. Mortality curves were superimposable, including curves according to type of HF and LVEF. The rates of missing data in the FRESH registry were 2.3-8.4% for clinical characteristics and 17.5% for hospitalizations during follow-up. The discrepancy rate for clinical characteristics was 3-13%. Hospitalization rates were significantly higher in the SNDS than in the registry cohort.The anonymous matching of an HF research cohort with a national health database is feasible, with a significant proportion of patients being accurately matched, and facilitates combination of clinical data and a reduced rate of losses to follow-up.
Published: 2022

14. Analysis of clinical pharmacist interventions in the COVID-19 units of a French university hospital

Author: Anne Deldicque, Pascal Odou, Jean-Baptiste Beuscart, Marc Lambert, Stéphanie Fry, Pascal de Groote, Arnaud Scherpereel, Jacques Desbordes, Bertrand Décaudin, E. Musy, Maxime Perez, Morgane Masse, and François Puisieux
Subjects: pharmacy, Drug, medicine.medical_specialty, media_common.quotation_subject, Psychological intervention, Pharmacy, Pharmacists, administration, 030226 pharmacology & pharmacy, Hospitals, University, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antithrombotic, Humans, Medicine, Prospective Studies, 030212 general & internal medicine, hospital, General Pharmacology, Toxicology and Pharmaceutics, Medical prescription, Prospective cohort study, Original Research, media_common, education, SARS-CoV-2, business.industry, COVID-19 Drug Treatment, Clinical pharmacy, pharmacy service, drug-related side effects and adverse reactions, intravenous, medical errors, Population study, business
Abstract: OBJECTIVES: The objectives were to compare clinical pharmacist interventions between two care groups: COVID-19-positive and COVID-19-negative patients, and to identify drugs that require particular attention, especially those involved in COVID-19 management. METHODS: A prospective cohort study was conducted on patients with positive and negative COVID-19 statuses admitted to Lille University Hospital over 1 month. Pharmaceutical analysis instigated interventions to rectify drug-related errors. For each pharmaceutical intervention (PI), the anatomical therapeutic chemical classification of the drug and the outcome of such an intervention were specified. RESULTS: The study included 438 patients. Prescription analysis led to 188 PIs performed on 118 patients (64 COVID-19-positive patients and 54 COVID-19-negative patients). Most drug-related problems were incorrect dosage representing 36.7% (69/188) of all interventions: 27.9% (29/104) for the COVID-19-positive group and 47.6% (40/84) for the COVID-19-negative group. The most frequent PI in 34% (64/188) of cases was terminating a drug: 27.9% (29/104) for the COVID-19-positive group and 47.6% (40/84) for the COVID-19-negative group. The main drug classes involved were antithrombotic agents (20.7%, 39/188), antibacterials for systemic use (13.8%, 26/188) and drugs for gastric acid-related disorders (6.4%, 12/188). Study population was limited to a single centre over 1 month. CONCLUSION: No difference in PI was noted between the two groups. The presence of pharmacists led to a reduction in drug-related prescription problems, especially for antithrombotic and antibacterial drugs for both groups. Clinical pharmacy commitment in such a pandemic is therefore important.
Published: 2021

15. Cardiac Outcomes in Adults With Mitochondrial Diseases

Author: Konstantinos Savvatis, Christoffer Rasmus Vissing, Lori Klouvi, Anca Florian, Mehjabin Rahman, Anthony Béhin, Abdallah Fayssoil, Marion Masingue, Tanya Stojkovic, Henri Marc Bécane, Nawal Berber, Fanny Mochel, Denis Duboc, Bertrand Fontaine, Bjørg Krett, Caroline Stalens, Julie Lejeune, Robert D.S. Pitceathly, Luis Lopes, Malika Saadi, Thomas Gossios, Vincent Procaccio, Marco Spinazzi, Céline Tard, Pascal De Groote, Claire-Marie Dhaenens, Claire Douillard, Andoni Echaniz-Laguna, Ros Quinlivan, Michael G. Hanna, Ali Yilmaz, John Vissing, Pascal Laforêt, Perry Elliott, Karim Wahbi, Queen Mary University of London (QMUL), IT University of Copenhagen (ITU), Association française contre les myopathies (AFM-Téléthon), University Hospital Münster - Universitaetsklinikum Muenster [Germany] (UKM), University College of London [London] (UCL), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Raymond Poincaré [Garches], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Cité (UPCité), Sorbonne Université (SU), Hôpital Cochin [AP-HP], Aristotle University of Thessaloniki, MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Biochimie et Génétique [Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Lille Neurosciences & Cognition - U 1172 (LilNCog), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP), Hôpital Claude Huriez [Lille], CHU Lille, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées (END-ICAP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), MR/S005021/1, Association Française contre les Myopathies, AFM, Medical Research Council, MRC: MR/S002065/1, Department of Health and Social Care, DH, University College London Hospitals NHS Foundation Trust, UCLH, NIHR Cambridge Biomedical Research Centre, This study was funded by grants from the Association Française contre les Myopathies (French Alliance against Myopathies), which was not involved in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, the preparation, review or approval of the manuscript, and nor in the decision to submit the manuscript for publication. Dr Pitceathly is supported by a Medical Research Council (United Kingdom) Clinician Scientist Fellowship (MR/S002065/1). Drs Pitceathly and Hanna receive funding from a Medical Research Council (United Kingdom) strategic award to establish an International Centre for Genomic Medicine in Neuromuscular Diseases (ICGNMD) (MR/S005021/1). Dr Lopes is supported by a Medical Research Council (United Kingdom) clinical academic partnership (CARP) award. Dr Quinlivan was funded by National Institute for Health and Care Research Biomedical Research Centre, University College Hospitals Foundation Trust. The University College London Hospitals/University College London Queen Square Institute of Neurology sequencing facility receives a proportion of funding from the Department of Health's National Institute for Health and Care Research Biomedical Research Centre’s funding scheme. The clinical and diagnostic 'Rare Mitochondrial Disorders' Service in London is funded by the U.K. NHS Highly Specialised Commissioners. Dr Elliott has received consultancy fees from Pfizer, Sanofi, Sarepta, DinaQor, Freeline, Novo Nordisk, and Bristol Myers Squibb. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Subjects: Adult, conduction disease, mitochondrial diseases, [SDV]Life Sciences [q-bio], heart failure, sudden death, Heart, Stroke Volume, Prognosis, DNA, Mitochondrial, Ventricular Function, Left, single large-scale deletions, Risk Factors, Humans, Hypertrophy, Left Ventricular, Cardiology and Cardiovascular Medicine, G%22">m3243A>G
Abstract: International audience; Background: Patients with mitochondrial diseases are at risk of heart failure (HF) and arrhythmic major adverse cardiac events (MACE). Objectives: We developed prediction models to estimate the risk of HF and arrhythmic MACE in this population. Methods: We determined the incidence and searched for predictors of HF and arrhythmic MACE using Cox regression in 600 adult patients from a multicenter registry with genetically confirmed mitochondrial diseases. Results: Over a median follow-up time of 6.67 years, 29 patients (4.9%) reached the HF endpoint, including 19 hospitalizations for nonterminal HF, 2 cardiac transplantations, and 8 deaths from HF. Thirty others (5.1%) reached the arrhythmic MACE, including 21 with third-degree or type II second-degree atrioventricular blocks, 4 with sinus node dysfunction, and 5 sudden cardiac deaths. Predictors of HF were the m.3243A>G variant (HR: 4.3; 95% CI: 1.8-10.1), conduction defects (HR: 3.0; 95% CI: 1.3-6.9), left ventricular (LV) hypertrophy (HR: 2.6; 95% CI: 1.1-5.8), LV ejection fraction
Published: 2022

16. Relative impact of bleedings over ischaemic events in patients with heart failure: insights from the CARDIONOR registry

Author: Christophe Bauters, Pascal de Groote, Guillaume Schurtz, Nicolas Lamblin, Gilles Lemesle, and Sandro Ninni
Subjects: medicine.medical_specialty, Heart failure, Major bleeding, 030204 cardiovascular system & hematology, Anticoagulation, 03 medical and health sciences, 0302 clinical medicine, Original Research Articles, Internal medicine, Antithrombotic, medicine, Diseases of the circulatory (Cardiovascular) system, Cumulative incidence, Original Research Article, 030212 general & internal medicine, Myocardial infarction, Stroke, business.industry, Hazard ratio, Atrial fibrillation, medicine.disease, Confidence interval, RC666-701, Cardiology and Cardiovascular Medicine, business
Abstract: Aims Major bleeding events in heart failure (HF) patients are poorly described. We sought to investigate the importance of major bleeding and its impact on outcomes in HF patients. Methods and results We analysed incident bleeding and ischaemic events during a 3 year follow‐up in 2910 HF outpatients included in a prospective multicentre registry. Major bleeding was defined as a Type ≥3 bleed using the Bleeding Academic Research Consortium definition. Ischaemic event was a composite of ischaemic stroke and myocardial infarction. Events were adjudicated by a blinded committee. At inclusion, most patients (89%) received at least one antithrombotic: anticoagulation (53.9%) and/or antiplatelet therapy (46.2%). Bleeding occurred in 111 patients {3 year cumulative incidence: 3.6% [95% confidence interval (CI) 3.0–4.3]} and ischaemic events in 102 patients [3 year cumulative incidence: 3.3% (95% CI 2.7–4.0)]. Most bleedings were Bleeding Academic Research Consortium 3a (32.5%) or 3b (31.5%). Most frequent sites of bleeding were gastrointestinal (40.6%) and intracranial (27.9%). Variables associated with bleeding were atrial fibrillation [hazard ratio (HR) = 2.63 (95% CI 1.66–4.19), P
Published: 2020

17. Circulating proteomic signature of early death in heart failure patients with reduced ejection fraction

Author: Vincent Vandewalle, Audrey Hulot, Guillemette Marot, Christophe Bauters, Florence Pinet, Pascal de Groote, Maxime Brunin, Olivia Beseme, Marie Cuvelliez, Philippe Amouyel, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Remodeling in Valvulopathy and Heart Failure [CHU Rouen] (FHU REMOD-VHF ), CHU Rouen, Normandie Université (NU)-Normandie Université (NU), MOdel for Data Analysis and Learning (MODAL), Inria Lille - Nord Europe, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Laboratoire Paul Painlevé - UMR 8524 (LPP), Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-École polytechnique universitaire de Lille (Polytech Lille)-Université de Lille, Sciences et Technologies, BILILLE, This work was supported by grants from the French Clinical Research Infrastructure Network INI-CRCT (Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists), the E.U. FP7 HOMAGE (305507), 'Agence Nationale de Recherche' 15-CEA-U16/'Direction Générale de l’Offre de Soins' (5–013) and CHRU de Lille (Bonus H2018). We acknowledge Somalogic Inc. as the provider of the proteomics analysis and EdgeLeap B.V. for the systems biology analysis., Laboratoire Paul Painlevé (LPP), Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille-Centre National de la Recherche Scientifique (CNRS)-Université de Lille, Sciences et Technologies-Inria Lille - Nord Europe, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-École polytechnique universitaire de Lille (Polytech Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Laboratoire Paul Painlevé - UMR 8524 (LPP), Pinet, Florence, Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE], METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, and Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167
Subjects: Oncology, Male, Proteomics, medicine.medical_specialty, Proteome, [SDV]Life Sciences [q-bio], lcsh:Medicine, Context (language use), Cardiovascular System, Article, Gene regulatory networks, Prognostic markers, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Risk Factors, Internal medicine, Cause of Death, Medicine, Humans, lcsh:Science, Cathepsin S, Heart Failure, Ejection fraction, business.industry, lcsh:R, Middle Aged, medicine.disease, Blood proteins, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Extracellular Matrix, [SDV] Life Sciences [q-bio], Clinical research, Heart failure, Biomarker (medicine), Female, lcsh:Q, business, Extracellular matrix organization
Abstract: Background: Heart failure (HF) remains a main cause of mortality worldwide. Risk stratification of patients with systolic chronic HF is critical to identify those who may benefit from advanced HF therapies. The aim of this study is to identify plasmatic proteins that could predict early death of HF patients. Methods: The subproteome targeted by the aptamer-based assay (SOMAscan) of 1310 proteins was profiled in blood samples from 168 HF patients with reduced ejection fraction hospitalized in CHRU de Lille. Patient's outcome was assessed 3 years after inclusion. Findings: Among the 1310 proteins, 203 were significantly modulated between dead and alive patients (Wilcoxon tests, FDR 5%). The INCA molecular network was built using these 203 proteins and contained 2881 molecules (1639 proteins, 1072 microRNAs, 170 metabolites). To assess mechanistic context of HF, molecules were assigned to 34 clusters annotated to biological pathways from Gene Ontology. Analysis of the INCA network model allowed to highlight extracellular matrix organization as mechanism involved in HF. In parallel, an adaptive LASSO was performed on these 203 proteins and six proteins were selected as candidates to predict early death of HF patients: complement C3, cathepsin S and FAM107B were decreased and MAPKAPK5, MMP1 and MMP7 increased in dead patients compared with patients alive. By conventional assays, complement C3, MMP1 and MMP7 were validated but not cathepsin S due to the low sensitivity and specificity of the assay used. Interpretation: A proteomic signature of 6 plasma proteins allows identifying HF patients with a risk of early death. Funding Statement: This work was supported by grants from French Clinical Research Infrastructure Network INI-CRT (Investigation Network Initiative-Cardiovascular and Renal Clinical Trialists), the E.U. FP7 HOMAGE (305507), “Agence Nationale de Recherche” 15-CEA-U16/”Direction Generale de l'Offre de Soins” (5- 013) and CHRU de Lille (Bonus H2018).We acknowledged Somalogic Inc as the provider of the proteomics analysis and EdgeLeap B.V. for the system biology analysis. Declaration of Interests: MC, VV, MB, OB, AH, PDG, PA, CB, GM, FP have no conflict of interest to disclose for the study performed. Ethics Approval Statement: The INCA study was approved by the ethics committee of the “Centre Hospitalier de Lille” (CP98/94, 5 November 1998) , and written informed consent was obtained for each patient.
Published: 2019

18. Multicentric randomized evaluation of a tricuspid valve percutaneous repair system (clip for the tricuspid valve) in the treatment of severe secondary tricuspid regurgitation Tri.Fr Design paper

Author: Erwan Donal, Guillaume Leurent, Anne Ganivet, Philip Lurz, Augustin Coisne, Pascal De Groote, Stephane Lafitte, Lionel Leroux, Nicole Karam, Loic Biere, Frederic Rouleau, Catherine Sportouch, Julien Dreyfus, Mohammed Nejjari, Jean-Michel Josselin, Amedeo Anselmi, Elena Galli, Emma Bajeux, Patrice Guerin, Jean-François Obadia, Jean-Noel Trochu, Emmanuel Oger, CHU Pontchaillou [Rennes], Laboratoire Traitement du Signal et de l'Image (LTSI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Leipzig University, CHU Lille, CHU Bordeaux [Bordeaux], Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Clinique du Millénaire - Oc Santé [Montpellier], Oc Santé [Montpellier], Centre cardiologique du Nord (CCN), Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centre hospitalier universitaire de Nantes (CHU Nantes), Hospices Civils de Lyon (HCL), Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)
Subjects: Heart Valve Prosthesis Implantation, Cardiac Catheterization, [SDV]Life Sciences [q-bio], heart failure, General Medicine, 030204 cardiovascular system & hematology, Surgical Instruments, Severity of Illness Index, Tricuspid Valve Insufficiency, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Treatment Outcome, Humans, Radiology, Nuclear Medicine and imaging, 030212 general & internal medicine, Tricuspid Valve, prognosis, transoesophageal echocardiography, Cardiology and Cardiovascular Medicine, tricuspid regurgitation
Abstract: Aims Tricuspid regurgitation (TR) is associated with significant morbidity and mortality. Its independent prognostic role has been repeatedly demonstrated. However, this valvular heart condition is largely undertreated because of the increased risk of surgical repair. Recently, transcatheter techniques for the treatment of TR have emerged, but their implications for the clinical endpoints are still unknown. Methods and results The Tri.fr trial will be a multicentre, controlled, randomized (1:1 ratio), superior, open-label, and parallel-group study conducted in 300 patients with severe secondary TR that is considered non-surgical by heart teams. Inclusion will be possible only after core laboratory review of transthoracic and transoesophageal echocardiography and after validation by the clinical eligibility committee. A description of the mechanisms of the TR will be conducted by the core laboratory. Atrial or ventricular impacts on the severity of the secondary TR will be taken into account for the randomization. The patients will be followed for 12-month, and the primary outcome will be the Packer composite clinical endpoint [combining New York Heart Association class, patient global assessment (PGA), and major cardiovascular events]. It will test the hypothesis that a tricuspid valve percutaneous repair strategy using a clip dedicated to the tricuspid valve is superior to best guideline-directed medical therapy in symptomatic patients with severe secondary TR. Conclusion Tri.fr will be the first randomized, academic, multicentre study testing the value of percutaneous correction in patients with severe secondary TR.
Published: 2021

19. Cytokines as prognostic biomarkers in pulmonary arterial hypertension

Author: Athénaïs Boucly, Ly Tu, Christophe Guignabert, Christopher Rhodes, Pascal De Groote, Grégoire Prévot, Emmanuel Bergot, Arnaud Bourdin, Antoine Beurnier, Anne Roche, Mitja Jevnikar, Xavier Jaïs, David Montani, Martin R. Wilkins, Marc Humbert, Olivier Sitbon, and Laurent Savale
Subjects: Pulmonary and Respiratory Medicine
Abstract: BackgroundRisk stratification and assessment of disease progression in patients with pulmonary arterial hypertension (PAH) are challenged by the lack of accurate disease-specific and prognostic biomarkers. To date, brain natriuretic peptide (BNP) and/or its N-terminal fragment (NT-proBNP) are the only markers for right ventricular dysfunction used in clinical practice, in association with echocardiographic and invasive haemodynamic variables to predict outcome in patients with PAH.MethodsThis study was designed to identify an easily measurable biomarker panel in the serum of 80 well-phenotyped PAH patients with idiopathic, heritable or drug-induced PAH at baseline and at first follow-up. The prognostic value of identified cytokines of interest was secondly analysed in an external validation cohort of 125 PAH patients.ResultsAmong the 20 biomarkers studied with the multiplex Ella platform, we identified a three-biomarker panel composed of β-NGF, CXCL9 and TRAIL that were independently associated with prognosis both at the time of PAH diagnosis and at the first follow-up after initiation of PAH therapy. β-NGF and CXCL9 were predictors of death or transplantation, whereas high levels of TRAIL were associated with a better prognosis. Furthermore, the prognostic value of the three cytokines was more powerful for predicting survival than usual non-invasive variables (New York Heart Association Functional Class, 6-min walk distance and BNP/NT-proBNP). The results were validated in a fully independent external validation cohort.ConclusionThe monitoring of β-NGF, CXCL9 and TRAIL levels in serum should be considered in the management and treatment of patients with PAH to objectively guide therapeutic options.
Published: 2022

20. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options

Author: Erwan Donal, Jean-Noël Trochu, Damien Logeart, Michel Galinier, Jean-Sébastien Hulot, Pascal de Groote, Yves Juillière, Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Faculté de Médecine [Rangueil], Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Cité (UPCité), CHU Lille, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Bayer Healthcare SAS, Jonchère, Laurent, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse], and Université de Paris (UP)
Subjects: vericiguat, Disease, Bioinformatics, Heterocyclic Compounds, 2-Ring, ventricular remodeling, 03 medical and health sciences, chemistry.chemical_compound, Soluble Guanylyl Cyclase, 0302 clinical medicine, Pharmacotherapy, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, heart failure (hf), Humans, Medicine, Pharmacology (medical), Ventricular remodeling, cGMP pathway, Cyclic guanosine monophosphate, Heart Failure, Pharmacology, heart failure hospitalization (hfh), heart failure with reduced ejection fraction (hfref), business.industry, Mechanism (biology), sGC stimulator, reduced left ventricular ejection fraction (lvef), Phosphodiesterase, Stroke Volume, General Medicine, medicine.disease, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Pyrimidines, chemistry, Mechanism of action, 030220 oncology & carcinogenesis, Heart failure, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, worsening chronic heart failure (WCHF)), medicine.symptom, business, 030217 neurology & neurosurgery, soluble guanylate cyclase (sGC)
Abstract: International audience; Introduction The significant morbidity and mortality in patients with heart failure (HF), notably in the most advanced forms of the disease, justify the need for novel therapeutic options. In the last year, the soluble guanylate cyclase (sGC) stimulator, vericiguat, has drawn the attention of the medical community following the report of reduced clinical outcomes in patients with worsening chronic HF (WCHF).Areas Covered The authors review the available data on the mechanism of action of vericiguat (cyclic guanosine monophosphate (cGMP) pathway), its clinical development program, its role in HF management, and its future positioning in the therapeutic recommendations.Expert opinion cGMP deficiency has deleterious effects on the heart and contributes to the progression of HF. Different molecules, including nitric oxide (NO) donors, phosphodiesterase inhibitors, and natriuretic peptides analogues, target the NO-sCG-cGMP pathway but have yielded conflicting results in HF patients. Vericiguat acts as a sGC stimulator thus targeting the NO-sGC-cGMP pathway by a different mechanism that complements the current pharmacotherapy for HF. Vericiguat has shown an additional statistical add-on therapy efficacy by reducing morbi-mortality in patients with WCHF. A better evaluation of HF severity might be an important determinant to guide the use of vericiguat among the available therapies.
Published: 2021

21. Right heart catheterization in advanced systolic heart failure. What are the most useful haemodynamic parameters for risk stratification?

Author: Pascal de Groote, Marie Delobelle, Eléonore Hebbar, Thomas Mercier, Marie Fertin, Céline Goéminne, Anju Duva Pentiah, André Vincentelli, Christophe Bauters, and Nicolas Lamblin
Subjects: Heart Failure, Cardiac Catheterization, Hypertension, Pulmonary, Hemodynamics, Humans, General Medicine, Cardiology and Cardiovascular Medicine, Risk Assessment, Heart Failure, Systolic, Retrospective Studies
Abstract: Previous studies have shown that pulmonary hypertension is a predictor of mortality in patients with systolic heart failure (SHF). Persistent pulmonary hypertension after a reactivity test is associated with a worse outcome after transplantation. Recent studies have shown the utility of different haemodynamic parameters.To define best haemodynamic parameters for risk stratification in patients with advanced systolic heart failure.We included 425 consecutive patients who underwent a right heart catheterization with an inotropic challenge if indicated.During a median (interquartile range) follow-up of 1.67 (0.49-4.49) years, there were 151 major cardiac events (126 cardiovascular deaths and 25 postoperative deaths after ventricular assist device implantation or heart transplantation). The most powerful independent predictors of major cardiac events were baseline right atrial pressure (RAP) (hazard ratio [HR]: 1.09, 95% confidence interval [CI]: 1.06-1.12; P0.0001) and baseline pulmonary vascular resistance (PVR) (HR: 1.10; 95% CI: 1.03-1.17; P=0.002). After inotropic challenge, the only independent predictor was mean pulmonary arterial pressure (mPAP) (HR: 1.06; 95% CI: 1.03-1.09; P0.0001). The combination of PVR (≤or3 Wood units), RAP (or≥9mmHg) and mPAP after the inotropic challenge (≤or30mmHg) was the best predictor of major events.We suggest using a simple algorithm based on baseline PVR, baseline RAP and mPAP after the inotropic challenge for the risk stratification of stable patients with advanced systolic heart failure.
Published: 2021

22. Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23

Author: Magdalena Harakalova, Benjamin Meder, Philippe Charron, Manuel Gómez-Bueno, Jorg J. A. Calis, François Cambien, David-Alexandre Trégouët, Maurizia Grasso, Steven McGinn, Uwe Völker, Thomas Meitinger, Stefan Weiss, L. Duboscq-Bidot, Richard Dorent, Vera Regitz-Zagrosek, Folkert W. Asselbergs, Hélène Blanché, Olivier Dubourg, Patrick Lacolley, Pierre Boutouyrie, Delphine Bacq-Daian, Vincent Fontaine, Volker Ruppert, Marine Germain, K Lehnert, Jean-Noël Trochu, Stuart A. Cook, Angélique Curjol, Brendan J. Keating, Ibticem Raji, Anne Boland, J. Erdmann, Michael Morley, Jean-François Aupetit, Paloma Remior, Luigi Tavazzi, Gérard Roizès, Michal Mokry, Konstantin Strauch, Richard Isnard, Jean-Philippe Empana, Robert Olaso, Kenneth B. Marguiles, Zofia T. Bilińska, Stephan B. Felix, Marcus Dörr, Thomas P. Cappola, Stefan Blankenberg, Jan Haas, Céline Besse, Jean-François Deleuze, Christine E. Seidman, Christian Hengstenberg, Jessica van Setten, Hakon Hakonarson, Sanjay K Prasad, Daiane Hemerich, Pascal de Groote, Thomas Wichter, Alain van Mil, Michel Komajda, Renee Maas, Carole Proust, Declan P. O'Regan, Xavier Jouven, Ganapathi Varma Saripella, Georgios Kararigas, Eloisa Arbustini, Jin Li, Klaus Stark, Laurent Fauchier, Flavie Ader, Melanie Waldenberger, Martina Müller-Nurasyid, Eric Villard, Sophie Garnier, Cardiology, Imperial College Healthcare NHS Trust- BRC Funding, British Heart Foundation, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Cardiologie [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Centre hospitalier Saint-Joseph [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Génétique Cytogénétique et Embryologie [CHU Pitié-Salpêtrière], Assistance publique-Hôpitaux de Paris, Fondation Leducq, Société Française de Cardiologie, Deutsche Forschungsgemeinschaft, Helmholtz Zentrum München, Université de Bordeaux, Medical Research Council, ANR-10-LABX-0013,GENMED,Medical Genomics(2010), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University Medical Center [Utrecht], Universität Greifswald - University of Greifswald, German Center for Cardiovascular Research (DZHK), Berlin Institute of Health (BIH), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], University of Pennsylvania, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), National Heart Centre Singapore (NHCS), Children’s Hospital of Philadelphia (CHOP ), University of Regensburg, Royal Brompton Hospital, Imperial College London, Istituti Clinici Scientifici Maugeri [Pavia] (IRCCS Pavia - ICS Maugeri), Helmholtz Zentrum München = German Research Center for Environmental Health, Ludwig-Maximilians-Universität München (LMU), Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), University Medical Center of the Johannes Gutenberg-University Mainz, Perelman School of Medicine, Harvard Medical School [Boston] (HMS), University of Iceland [Reykjavik], Heidelberg University, Stanford University Medical School, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Universität zu Lübeck = University of Lübeck [Lübeck], Universitätklinikum Gießen und Marburg GmbH, Maria Cecilia Hospital [Cotignola], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre hospitalier Saint Joseph - Saint Luc [Lyon], National Institute of Cardiology [Varsovie, Pologne], University of Medicine Greifswald, Centre de Référence Maladies Cardiaques Héréditaires, Centre National de Recherche en Génomique Humaine (CNRGH), Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Laboratory of Excellence GENMED [Paris] (Medical Genomics), Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], Swedish University of Agricultural Sciences (SLU), Centre d'Etude du Polymorphisme Humain (CEPH), Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Fondation Jean Dausset-Université Paris Cité (UPCité), Faculté de Pharmacie de Paris - Université Paris Descartes (UPD5 Pharmacie), Université Paris Descartes - Paris 5 (UPD5), Groupe Hospitalier Paris Saint Joseph, Fondation Jean Dausset - Centre d’Etudes du Polymorphisme Humain [Paris] (CEPH), and University College of London [London] (UCL)
Subjects: Cardiac & Cardiovascular Systems, Cardiomyopathy, Dilated/genetics, [SDV]Life Sciences [q-bio], Signal Transducing/genetics, Dilated cardiomyopathy, Genome-wide association study, Adaptor Proteins, Signal Transducing/genetics, 030204 cardiovascular system & hematology, TAURINE, 0302 clinical medicine, GWAS, Medicine, POSITION STATEMENT, 1102 Cardiorespiratory Medicine and Haematology, Genetics, 0303 health sciences, education.field_of_study, Genetic Predisposition to Disease/genetics, Adaptor Proteins, 4C-sequencing, Polymorphism, Single Nucleotide/genetics, Genetic risk score, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, Single Nucleotide/genetics, Cardiomyopathy, Dilated, Cardiomyopathy, Population, Locus (genetics), Single-nucleotide polymorphism, Polymorphism, Single Nucleotide, Chromosomes, 03 medical and health sciences, Systolic/genetics, Heart Failure, Systolic/genetics, SNP, Animals, Humans, Genetic Predisposition to Disease, Allele, Polymorphism, education, Imputation, Adaptor Proteins, Signal Transducing, 030304 developmental biology, Heart Failure, Science & Technology, business.industry, WORKING GROUP, 1103 Clinical Sciences, medicine.disease, Genetic architecture, Cardiovascular System & Hematology, Dilated/genetics, Cardiovascular System & Cardiology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, Apoptosis Regulatory Proteins, Heart Failure, Systolic, Genome-Wide Association Study
Abstract: Aims Our objective was to better understand the genetic bases of dilated cardiomyopathy (DCM), a leading cause of systolic heart failure. Methods and results We conducted the largest genome-wide association study performed so far in DCM, with 2719 cases and 4440 controls in the discovery population. We identified and replicated two new DCM-associated loci on chromosome 3p25.1 [lead single-nucleotide polymorphism (SNP) rs62232870, P = 8.7 × 10−11 and 7.7 × 10−4 in the discovery and replication steps, respectively] and chromosome 22q11.23 (lead SNP rs7284877, P = 3.3 × 10−8 and 1.4 × 10−3 in the discovery and replication steps, respectively), while confirming two previously identified DCM loci on chromosomes 10 and 1, BAG3 and HSPB7. A genetic risk score constructed from the number of risk alleles at these four DCM loci revealed a 3-fold increased risk of DCM for individuals with 8 risk alleles compared to individuals with 5 risk alleles (median of the referral population). In silico annotation and functional 4C-sequencing analyses on iPSC-derived cardiomyocytes identify SLC6A6 as the most likely DCM gene at the 3p25.1 locus. This gene encodes a taurine transporter whose involvement in myocardial dysfunction and DCM is supported by numerous observations in humans and animals. At the 22q11.23 locus, in silico and data mining annotations, and to a lesser extent functional analysis, strongly suggest SMARCB1 as the candidate culprit gene. Conclusion This study provides a better understanding of the genetic architecture of DCM and sheds light on novel biological pathways underlying heart failure.
Published: 2021

23. Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1

Author: Pamela Moceri, Maria-Rosa Ghigna, Olivier Sitbon, Céline Chabanne, Marc Humbert, Pascal de Groote, Pierre Wolkenstein, Julie Traclet, Xavier Mignard, Emmanuel Bergot, François Goupil, Delphine Bourlier, Xavier Jaïs, Etienne-Marie Jutant, David Montani, Frédéric Perros, Laurent Bertoletti, Jean-Pierre Gueffet, Gérald Simonneau, Thibaud Soumagne, Nicolas Favrolt, Grégoire Prévot, Cécile Tromeur, Pierre-Yves Brillet, Barbara Girerd, Mitja Jevnikar, Fabrice Bauer, Ari Chaouat, Pascal Magro, Raphael Borie, Elie Fadel, Laurent Savale, and Claire Dauphin
Subjects: Pulmonary and Respiratory Medicine, Adult, Male, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Lung Neoplasms, Neurofibromatosis 1, Adolescent, Hypertension, Pulmonary, Critical Care and Intensive Care Medicine, Gastroenterology, Young Adult, Internal medicine, medicine, Humans, Neurofibromatosis, neoplasms, Neurofibromin 1, business.industry, Interstitial lung disease, Middle Aged, medicine.disease, Prognosis, Phenotype, Pulmonary hypertension, eye diseases, nervous system diseases, Female, France, business, Complication, Lung Transplantation
Abstract: Rationale: Pulmonary hypertension (PH) associated with neurofibromatosis type 1 (NF1) is a rare and largely unknown complication of NF1.Objectives: To describe characteristics and outcomes of PH-NF...
Published: 2020

24. Epidemiological characteristics and therapeutic management of patients with chronic heart failure who use smartphones: Potential impact of a dedicated smartphone application (report from the OFICSel study)

Author: Jean-Etienne Ricci, Diane Bodez, Ugo Vergeylen, Emmanuelle Berthelot, C. Chong-Nguyen, Barnabas Gellen, Théo Pezel, Marie Christine Iliou, L. Bonnefous, Florence Beauvais, Etienne Audureau, Mélanie Bézard, Michel Galinier, Pascal de Groote, Yves Juillière, Pierre Raphael, Marie-Claire Boiteux, Thibaud Damy, Fabrice Bauer, and Jean Gauthier
Subjects: Male, medicine.medical_specialty, Health Knowledge, Attitudes, Practice, Databases, Factual, Population, 030204 cardiovascular system & hematology, Smartphone application, Patient Readmission, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Patient Education as Topic, Risk Factors, Diabetes mellitus, Epidemiology, medicine, Humans, Transitional care, 030212 general & internal medicine, Registries, education, Aged, Heart Failure, Potential impact, education.field_of_study, business.industry, Atrial fibrillation, General Medicine, Transitional Care, Continuity of Patient Care, Middle Aged, medicine.disease, Mobile Applications, Patient Discharge, Telemedicine, Treatment Outcome, Heart failure, Chronic Disease, Female, Medical emergency, France, Smartphone, Cardiology and Cardiovascular Medicine, business, Risk Reduction Behavior
Abstract: Summary Background The effectiveness of transitional care services for patients discharged from hospital after acute heart failure is challenging, especially in terms of reducing subsequent heart failure hospitalizations. The increased adoption of smartphone applications in society offers a new opportunity to interact with patients to avoid rehospitalization. Thus, electronic health (e-health) can enhance the impact of existing therapeutic education programmes. Aims To determine the prevalence of smartphone use among patients with chronic heart failure, and to assess the epidemiological characteristics and therapeutic management of these patients, with a broader aim of developing smartphone-based therapeutic education programmes for patients. Methods The French Observatoire francais de l’insuffisance cardiaque et du sel (OFICSel) registry was conducted in 2017 by 300 cardiologists, and included both inpatients and outpatients who had been hospitalized for heart failure at least once in the previous 5 years. Data collection included demographic and heart failure-related variables, which were provided by the cardiologist and by the patient via a questionnaire. Results Among the 2822 patients included, 2517 completed the questionnaire. Of this total, 907 patients (36%) were smartphone users. Compared with non-users, smartphone users were younger, were more frequently men, more frequently lived in cities, had a higher educational level and were more frequently professionally active. Smartphone users less frequently had diabetes, hypertension, atrial fibrillation or ischaemic cardiopathy. Only 22% of patients were actively participating in a therapeutic education programme. Conclusion Smartphones were used by more than one-third of patients with heart failure in France in 2017, underscoring the feasibility of developing a smartphone application to deliver therapeutic education to the population with chronic heart failure.
Published: 2019

25. Assessment of potential heart donors: A statement from the French heart transplant community

Author: Richard Dorent, Fabrice Bauer, Pascale Boissonnat, Guillaume Lebreton, Damien Logeart, Emmanuelle Vermes, Fabrice Ivanes, Phalla Ou, Céline Goéminne, Estelle Gandjbakhch, Julien Amour, Laurent Sebbag, Eric Epailly, Pascal de Groote, Erwan Flecher, Karine Nubret, Jean-François Obadia, Philippe Chevalier, and Soulef Guendouz
Subjects: Male, Brain Death, Cardiac Catheterization, medicine.medical_specialty, Consensus, Health Status, medicine.medical_treatment, Economic shortage, 030204 cardiovascular system & hematology, Risk Assessment, Medical Records, Donor Selection, Electrocardiography, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Risk Factors, medicine, Humans, Medical history, 030212 general & internal medicine, Organ donation, Intensive care medicine, Donor management, Heart transplantation, medicine.diagnostic_test, business.industry, General Medicine, Middle Aged, Tissue Donors, Cardiac Imaging Techniques, Donor heart, Heart Transplantation, Female, France, Cardiology and Cardiovascular Medicine, business, Biomarkers
Abstract: Assessment of potential donors is an essential part of heart transplantation. Despite the shortage of donor hearts, donor heart procurement from brain-dead organ donors remains low in France, which may be explained by the increasing proportion of high-risk donors, as well as the mismatch between donor assessment and the transplant team's expectations. Improving donor and donor heart assessment is essential to improve the low utilization rate of available donor hearts without increasing post-transplant recipient mortality. This document provides information to practitioners involved in brain-dead donor management, evaluation and selection, concerning the place of medical history, electrocardiography, cardiac imaging, biomarkers and haemodynamic and arrhythmia assessment in the characterization of potential heart donors.
Published: 2018

26. Association of Mortality With Aortic Stenosis Severity in Outpatients

Author: Robert Lallemant, Damien Broucqsault, Karine Bauley, Jean-Pierre Coulomb, François Destombes, Olivier Hennebert, Jérôme Haye, David Montaigne, Xavier Dujardin, Octave Equine, Pascal de Groote, Bruno Fournier, Christophe Cordier, Hélène Ridon, Moulay Alaoui, Karim Chachoua, Messaoud Kouidri, Christophe Mycinski, Gérard Houdain, Aurélie Musschoot, Vincent Hennebelle, Rémy Lubret, Maïwenn Clement-Dupont, Philippe Lejeune, Julien Voyez, Frédéric Biausque, Sylvie Tondeux, Elise Dassonvalle, Antonio Gongora, Maxence Delomez, Michel Devillers, Nestor Lemaire, Augustin Coisne, Karima Ouchallal, Thibaud Meurice, Sébastien Caudmont, Bruno Vaquette, Nicolas Detis, Anne-Laure Madika, Laurence Avez-Lemaire, Dan Neicu, Charles Hudelo, Maud Wibaux, Dieudonné Tchatchoua, Thibault Hus, Laurent Carpentier, Nicolas Lamblin, Vladimir Cousin, Frédéric Mouquet, Marie Fertin, Thierry Jacquemart, Audrey Duchemin, Aida Ben Abda, Claire Vanesson, Max Pecheux, Belaid Jellouli, Mariam Arabidze, Rémy Viart, Mathilde Jacquelinet, Steve Werquin, Dauphine Garin, Yann Lefetz, Pascal Delsart, Mathieu Verhaeghe, Jean Becquart, Véronique Taverne, François Passard, Philippe Pruvost, Ahmed Amiar, Guillaume Ledieu, Hubert Vodoungnon, Anne-Sophie Polge, M. Richardson, Benoit Brullard, Arnaud Quercy, Eric Verbrugge, Christophe Bauters, Nima Endjah, Patrizio Lancellotti, Olivier Nugue, Karine Sautiere-Tricot, Gery Hannebicque, Alessandro Cosenza, Alain Petit, Valvenor Investigators, André Philias, Fanny Boudghene Stambouli, Luc Abramovici, François Leleu, Eric Decoulx, Guillaume de Geeter, Francis Kozlowski, Stéphanie Mouton, Anju Duva Pentiah, Rosario Pilato, Arthur Vaksmann, Kouroch Taghipour, Jean-Michel Bruffau, Benoit Segrestin, Alain Millaire, Dominique Vandamme, Akram Chmait, Lorraine Greffe, Patricia Langlois, Olivier Jabourek, Arnaud Hubert, Valérie Aumegeat, Christine Savoye, Rahma Ouardani, Antoine Jeu, Marc Sagot, Eléonore Hebbar, Philippe Marboeuf, Jean-Charles Aisenfarb, Bertrand Boutié, Samy Aghezzaf, Karine Pedelhez, Olivier Tricot, Jonathan Meurice, Hélène Bardet, and Olivia Domanski
Subjects: Male, medicine.medical_specialty, Time Factors, Severity of Illness Index, Sudden death, Asymptomatic, Death, Sudden, Aortic valve replacement, Interquartile range, Cause of Death, Internal medicine, Outpatients, medicine, Humans, Aged, Retrospective Studies, Original Investigation, business.industry, Incidence (epidemiology), Hazard ratio, Aortic Valve Stenosis, medicine.disease, Europe, Survival Rate, Stenosis, Echocardiography, Private practice, Aortic Valve, Cardiology, Female, medicine.symptom, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract: Importance Modern data regarding incidence and modes of death of patients with aortic stenosis (AS) are restricted to tertiary centers or studies of aortic valve replacement (AVR). Objective To provide new insights into the natural history of outpatients with native AS based on a large regionwide population study with inclusion by all cardiologists regardless of their mode of practice. Design, Setting, and Participants Between May 2016 and December 2017, consecutive outpatients with mild (peak aortic velocity, 2.5-2.9 m/s), moderate (peak aortic velocity, 3-3.9 m/s), and severe (peak aortic velocity, ≥4 m/s) native AS graded by echocardiography were included by 117 cardiologists from the Nord-Pas-de-Calais region in France. Analysis took place between August and November 2020. Main Outcomes and Measures Natural history, need for AVR, and survival of patients with AS were followed up. Indications for AVR were based on current guideline recommendations. Results Among 2703 patients (mean [SD] age, 76.0 [10.8] years; 1260 [46.6%] women), 233 (8.6%) were recruited in a university public hospital, 757 (28%) in nonuniversity public hospitals, and 1713 (63.4%) by cardiologists working in private practice. A total of 1154 patients (42.7%) had mild, 1122 (41.5%) had moderate, and 427 (15.8%) had severe AS. During a median (interquartile range) of 2.1 (1.4-2.7) years, 634 patients underwent AVR and 448 died prior to AVR. Most deaths were cardiovascular (200 [44.7%]), mainly associated with congestive heart failure (101 [22.6%]) or sudden death (60 [13.4%]). Deaths were noncardiovascular in 186 patients (41.5%) and from unknown causes in 62 patients (13.8%). Compared with patients with mild AS, there was increased cardiovascular mortality in those with moderate (hazard ratio, 1.47 [95% CI, 1.07-2.02]) and severe (hazard ratio, 3.66 [95% CI, 2.52-5.31]) AS. The differences remained significant when adjusted for baseline characteristics or in time-dependent analyses considering AS progression. In asymptomatic patients, moderate and mild AS were associated with similar cardiovascular mortality (hazard ratio, 0.99 [95% CI, 0.44-2.21]). Conclusions and Relevance While patients in this study with moderate AS had a slightly higher risk of cardiovascular death than patients with mild AS, this risk was much lower than that observed in patients with severe AS. Moreover, in asymptomatic patients, moderate and mild AS were associated with similar cardiovascular mortality.
Published: 2021

27. External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry

Author: Mitja Jevnikar, Laurent Savale, Grégoire Prévot, Xavier Jaïs, Arnaud Bourdin, Antoine Beurnier, David Montani, Vincent Cottin, Jason Weatherald, Olivier Sitbon, Marc Humbert, Pascal de Groote, Gérald Simonneau, François Picard, Ari Chaouat, Etienne-Marie Jutant, Athénaïs Boucly, and Delphine Horeau-Langlard
Subjects: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Portopulmonary hypertension, Heart disease, business.industry, medicine.drug_class, Walk distance, External validation, Risk management tools, medicine.disease, Pulmonary hypertension, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, medicine, Natriuretic peptide, 030212 general & internal medicine, Risk assessment, business
Abstract: IntroductionContemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.MethodsWe evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan–Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches.ResultsAt baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk.ConclusionsThe four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.
Published: 2021

28. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study

Author: Logeart, Damien, Isnard, Richard, Resche-Rigon, Matthieu, Seronde, Marie-France, de Groote, Pascal, Jondeau, Guillaume, Galinier, Michel, Mulak, Geneviève, Donal, Erwan, Delahaye, François, Juilliere, Yves, Damy, Thibaud, Jourdain, Patrick, Bauer, Fabrice, Eicher, Jean-Christophe, Neuder, Yannick, Trochu, Jean-Noël, Chantal, Ache Papillon, Nadia, Aissaoudi, François, Aupetit Jean, Christian, Baietto, Noël, Baille, Serge, Baleynaud, Jacques, Ballout, Claude, Barnay, Fabrice, Bauer, Bechetoille, Mohammed, Belhameche, Loïc, Belle, Sandrine, Bentzinger, Alain, Bergere, Philippe, Bernadet, Marie, Perron Jean, François, Bernasconi, Samia, Berranen, Annick, Bineau-Jorisse, Michel, Serrano, Christian, Boureux, Salim, Boutalba, Erik, Bouvier, Marc, Bouvier Jean, Françoise, Bragard Marie, Philippe, Brunel, Roland, Carlioz, Christophe, Charniot Jean, Christophe, Chavelas, Saïda, Cheggour, Pascal, Chevalet, Vlad, Ciobotaru, René, Codjia, Alain, Cohen Solal, Patrick, Coulon, Daniel, Czitrom, Nicolas, Dahdal, Philippe, De Corbiere, Pascal, De Groote, Olivier, De Sauniere, France, Deforet Marie, Alain, Lassabe, Michel, Mansour, François, Delahaye, Michel, Chuzeville, Arnaud, Dellinger, Jacques, Denis, Gilles, Dentan, Michèle, Desruennes, Sylvain, Destrac, Claude, Dib Jean, Rodies, Dimitriou, Philippe, Doazan Jean, Erwan, Donal, Pierre, Matali, Pierre, Dos Santos, Roland, Sananes, Jacques, Dujardin Jean, Hervé, Gallois, Eric, Durand, Michel, Desnos, Sophie, Durand, Florence, Durup, Laurent, Dutoit, J-C, Eicher, Abdellatif, El Hallak, Mariam, Elkohen, Elodie, Faveau, Michèle, Escande, Jean, Ettori, Laurent, Fauchier, François, Maillot, Jean-Pierre, Favier, Bertrand, Fontan, Patrick, Friocourt, Philippe, Fromage, Michel, Galinier, Daniel, Galley, Erik, Garbarz, Philippe, Garcon, Daniel, Garnier, Cédric, Gaxatte, Frédéric, Georger, Renaud, Gervais, Nachwan, Ghanem, Géraldine, Gibault, Clément, Charbonnel, Pierre, Gibelin, Patrice, Brocker, Michel, Gofard, Mohand, Goudjil, Gilbert, Habib, Maryline, Hamdan-Challe, Olivier, Hanon, Michèle, Pinson, Luc, Hittinger, David, Houpe, Agnes, Hyverts, Eva, Inorowicz, Richard, Isnard, Adi, Issa, Muntaser P, Jamal, Luc, Jannin-Manificat, Guillaume, Jondeau, Patrick, Jourdain, Marc, Joussen Jean, Alain, Juillard, Yves, Juilliere, David, Kenizou, Barbara, Lambert, Skander, Khechine, Robin, Zelinsky, Pierre, Lagorce, Maryse, Lescure, Pierre, Lantelme, Thierry, Laperche, Fabrice, Larrazet, Evelyne, Laurent, Philippe, Le Metayer, Patrick, Assyag, Julien, Lemoine, Rémy, Lepori, Benoit, Lequeux, Guillaume, Lhernault, Christine, Machuron, Dominique, Magnin, Nam, Mai, Hamid, Makki, Mounia, Malou, J Jacques, Marier, Jean-Pierre, Maroni, Michel, Martelet, Colette, Matagrin, Nicolas, Coquerel, Mestre-Fernandes, Damien, Metz, Christophe, Meune, Laurent, Michel, Sandrine, Migran, Olivier, Milleron, Catherine, Mimran, Christian, Montagnier, Christophe, Moreau, Yannick, Neuder, Laurent, Orion, Blandine, Ouattara, Joël, Belmin, Eric, Perchicot, Sandrine, Peyrot, Laurent, Poirette, Philippe, Pon-Gabrielsen, Isabelle, Poulain, Fabrice, Prunier, Mamy, Randriamora, Pierre, Raphael, Charles, Raynaud Jean, Guy, Rebuffat, Michel, Remond, Franck, Revel, François, Roubille, Rémi, Sabatier, Raïf, Sader, Robert, Sal, Carole, Saudubray, France, Seronde Marie, François-Xavier, Soto, Jocelyn, Souk Aloun, Benoit, Spillemaecker, Adel, Srour, Yves, Tabet Jean, Michel, Tartiere Jean, Guy, Thourot, Thierry, Tibi, Christophe, Tribouilloy, Noël, Trochu Jean, Eric, Verbrugge, François, Vinchon, and Khelil, Yaici
Published: 2013
Full Text: View/download PDF

29. ROLE AND FUNCTIONAL CHARACTERIZATION OF CUB-DOMAIN CONTAINING PROTEIN 1 (CDCP1) IN DILATED CARDIOMYOPATHY

Author: Duan Liu, Vishakantha Murthy, Florence Pinet, Silvana Pileggi, Pascal de Groote, Gregory D. Jenkins, Min Wang, Do Young Lim, Anthony Batzler, Thanh Thanh L. Nguyen, Dennis M. McNamara, Jordan D. Miller, Richard M. Weinshilboum, Runqing Huang, Luisa Mestroni, Michelle K. Skime, Naveen L. Pereira, Marco Merlo, and Simona Barlera
Subjects: business.industry, CDCP1, Medicine, Dilated cardiomyopathy, Cardiology and Cardiovascular Medicine, business, medicine.disease, CUB domain, Cell biology
Published: 2021

30. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial

Author: Nicolas Martin, Dénes Csonka, Marius M. Hoeper, Nick H. Kim, Michael J. Krowka, Emmanuelle Cottreel, Laurent Savale, Olivier Sitbon, Pascal de Groote, Jaume Bosch, Hypertension pulmonaire : physiopathologie et innovation thérapeutique (HPPIT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: Pulmonary and Respiratory Medicine, Endothelin Receptor Antagonists, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Placebo, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Double-Blind Method, law, Internal medicine, Hypertension, Portal, Clinical endpoint, Medicine, Humans, 030212 general & internal medicine, Macitentan, Aged, Portopulmonary hypertension, Pulmonary Arterial Hypertension, Sulfonamides, business.industry, Endothelin receptor antagonist, Middle Aged, medicine.disease, 3. Good health, Clinical trial, medicine.anatomical_structure, Pyrimidines, Treatment Outcome, 030228 respiratory system, chemistry, Vascular resistance, Female, Vascular Resistance, business
Abstract: No dedicated randomised clinical trials have evaluated therapies for pulmonary arterial hypertension in patients with portopulmonary hypertension. The endothelin receptor antagonist macitentan has demonstrated long-term efficacy in pulmonary arterial hypertension with a good hepatic safety profile. We aimed to evaluate efficacy and safety of macitentan in patients with portopulmonary hypertension.PORTICO was a phase 4 study done in 36 centres in seven countries, consisting of a 12-week double-blind period (randomly assigned 1:1 to macitentan 10 mg or placebo once daily) followed by a 12-week open-label period. Adults (≥18 years) with portopulmonary hypertension, a 6-minute walk distance of 50 m or more, and with pulmonary vascular resistance of 320 dyn·s·cmBetween June 23, 2015, and July 28, 2017, 85 patients were randomly assigned to macitentan (n=43) or placebo (n=42). At baseline, 54 (64%) were receiving background therapy for pulmonary arterial hypertension. Most patients were WHO functional class II (50, 59%) or III (33, 39%) with a mean 6-minute walk distance of 384·5 m (SD 103·9). At week 12, the geometric mean ratio of baseline pulmonary vascular resistance was 0·63 (95% CI 0·58-0·67) in the macitentan group and 0·98 (95% CI 0·91-1·05) in the placebo group, corresponding to a ratio of geometric mean for pulmonary vascular resistance of 0·65 (95% CI 0·59-0·72, p0·0001), which in turn represented a 35% (95% CI 28-41) reduction in pulmonary vascular resistance with macitentan versus placebo. During the double-blind period, 36 (84%) macitentan-treated and 33 (79%) placebo-treated patients had adverse events, and nine (21%) and six (14%), had serious adverse events. Four (9%) macitentan-treated patients had an adverse event leading to discontinuation versus none in the placebo group. The most frequent adverse event during the double-blind period was peripheral oedema (11 [26%] in the macitentan group and five [12%] in the placebo group).Macitentan significantly improved pulmonary vascular resistance in portopulmonary hypertension patients, with no hepatic safety concerns.Actelion Pharmaceuticals Ltd.
Published: 2019

31. Survival Improved in Patients Aged ≤ 70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France

Author: Pascal de Groote, Jonathan Giovannelli, Athénaïs Boucly, Jason Weatherald, Gérald Simonneau, Grégory Pugnet, Luc Mouthon, David Montani, Vincent Cottin, Delphine Bourlier, Grégoire Prévot, Olivier Sitbon, Marc Humbert, Ari Chaouat, Eric Hachulla, David Launay, and Claire Dauphin
Subjects: Pulmonary and Respiratory Medicine, Endothelin Receptor Antagonists, Male, medicine.medical_specialty, Combination therapy, Hypertension, Pulmonary, Critical Care and Intensive Care Medicine, Risk Assessment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Humans, 030212 general & internal medicine, Pulmonary wedge pressure, Correlation of Data, Associated Pulmonary Arterial Hypertension, Aged, Retrospective Studies, Scleroderma, Systemic, business.industry, Proportional hazards model, Endothelin receptor antagonist, Confounding, Hazard ratio, Age Factors, Middle Aged, Phosphodiesterase 5 Inhibitors, Survival Analysis, medicine.anatomical_structure, 030228 respiratory system, Vascular resistance, Drug Therapy, Combination, Female, France, Cardiology and Cardiovascular Medicine, business
Abstract: Background To date, nothing is known about the evolution of survival in systemic sclerosis-associated pulmonary arterial hypertension (PAH) over the last decade. Methods This study used a multivariate Cox regression model adjusted for clinically relevant baseline confounders to assess the association between the occurrence of death and date of PAH diagnosis comparing two periods of the same duration (2006-2011 vs 2012-2017). Interactions between the two diagnosis periods and baseline variables were tested. Results A total of 306 incident patients were included, 167 (54.6%) with a PAH diagnosis occurring in 2006 to 2011 and 139 (45.4%) in 2012 to 2017. No significant difference in survival was observed between patients diagnosed with PAH in 2012 to 2017 compared with those diagnosed in 2006 to 2011 (hazard ratio [HR], 0.76 [0.46-1.26]; P = .29). A significant interaction was observed between PAH diagnosis periods and age (P = .05). When stratifying according to age (based on the median age of 70 years), a significant increase was observed in survival in patients aged ≤ 70 years between the 2006 to 2011 period and the 2012 to 2017 period (HR, 0.40 [0.17-0.99]; P = .046) but not in older patients (HR, 1.29 [0.67-2.51]; P = .44). A significantly higher proportion of initial (ie, within the first 4 months) endothelin receptor antagonist/phosphodiesterase type 5 inhibitor combination therapy was observed in younger patients diagnosed from 2012 to 2017 vs those diagnosed from 2006 to 2011 (42.9% vs 19.5%; P = .002) but not in older patients. Conclusions Over the period 2006 to 2017, survival in systemic sclerosis-associated PAH improved over time in patients aged ≤ 70 years but not in older patients. Further investigations are needed to confirm this relation, as general improvement in medical care and management may also be a possible explanation.
Published: 2019

32. Right ventricular systolic function in heart failure: A long story but still the same question

Author: Pascal de Groote
Subjects: Heart Failure, medicine.medical_specialty, Systole, business.industry, Stroke Volume, General Medicine, Systolic function, Stroke volume, 030204 cardiovascular system & hematology, medicine.disease, Right ventricular ejection fraction, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Heart failure, Ventricular Function, Right, Cardiology, medicine, Humans, 030212 general & internal medicine, Cardiology and Cardiovascular Medicine, business
Published: 2016

33. Subacute right heart failure revealing three simultaneous causes of post-embolic pulmonary hypertension in metastatic dissemination of breast cancer

Author: Antoine Rauch, Flavien Vincent, Pascal de Groote, Marie Fertin, Guillaume Schurtz, Nicolas Lamblin, and Marion Classe
Subjects: medicine.medical_specialty, Thrombotic microangiopathy, Ambrisentan, business.industry, medicine.medical_treatment, Cardiogenic shock, medicine.disease, Pulmonary hypertension, Pulmonary embolism, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, 030220 oncology & carcinogenesis, Internal medicine, Heart failure, cardiovascular system, medicine, Cardiology, 030211 gastroenterology & hepatology, Radiology, Cardiology and Cardiovascular Medicine, business, Cardiac catheterization, medicine.drug
Abstract: A 72-year-old woman with history of breast cancer only treated surgically was referred to our department for pulmonary hypertension (PH) suspicion. Echocardiogram revealed elevated right ventricular systolic pressure. Computed tomography (CT) angiogram showed no pulmonary embolism (PE), but lung scan revealed two ventilation-perfusion mismatch areas. Right cardiac catheterization established precapillary PH. Despite treatment with PH specific therapy (sildenafil, ambrisentan, and epoprostenol), her condition worsened rapidly with acute right heart failure (RHF). She died 22 days after admission. Post-mortem microscopic examination showed a rare combination of PH etiologies consistent with metastasis of breast cancer in pulmonary vasculature including the rare pulmonary tumour thrombotic microangiopathy (PTTM).
Published: 2016

34. Accuracy of cardiac magnetic resonance imaging to rule out significant coronary artery disease in patients with systolic heart failure of unknown aetiology: Single-centre experience and comprehensive meta-analysis

Author: Gilles Lemesle, François Pontana, Anju Duva Pentiah, Nicolas Lamblin, Marine Baijot, Nicolas Debry, Eric Van Belle, Marie Fertin, Guillaume Schurtz, Christopher Hurt, Cedric Delhaye, Paul Lebert, Martine Remy-Jardin, Arnaud Sudre, Christophe Bauters, Pascal de Groote, Aurélie Manchuelle, and Patrizio Lancellotti
Subjects: Adult, Male, medicine.medical_specialty, Contrast Media, Coronary Artery Disease, 030204 cardiovascular system & hematology, Coronary Angiography, Severity of Illness Index, Ventricular Function, Left, Coronary artery disease, 03 medical and health sciences, 0302 clinical medicine, Cardiac magnetic resonance imaging, Predictive Value of Tests, Risk Factors, Internal medicine, medicine, Humans, cardiovascular diseases, 030212 general & internal medicine, Myocardial infarction, Registries, Aged, Ejection fraction, medicine.diagnostic_test, business.industry, Coronary Stenosis, Reproducibility of Results, Magnetic resonance imaging, Stroke Volume, General Medicine, Middle Aged, medicine.disease, Prognosis, Magnetic Resonance Imaging, Confidence interval, medicine.anatomical_structure, Heart failure, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Artery, Heart Failure, Systolic
Abstract: Summary Background Coronary artery disease (CAD) is the leading cause of systolic heart failure (HF). Cardiac magnetic resonance imaging (CMR) is a non-invasive technique that detects a myocardial infarction scar as subendocardial or transmural late gadolinium enhancement (st-LGE). Aim We sought to evaluate whether a lack of st-LGE could rule out CAD in new-onset systolic HF of unknown aetiology. Methods We included 232 consecutive patients with new-onset HF and left ventricular ejection fraction ≤ 35% who underwent both coronary angiography and CMR to assess HF aetiology. CAD was defined as the presence of coronary artery stenosis ≥ 50% on a coronary angiogram. We assessed sensitivity, specificity, and positive and negative likelihood ratios (PLR and NLR) of the presence of st-LGE to detect underlying CAD. A complementary meta-analysis of 11 studies (including ours) was also performed. Results In our study, 49 (21.1%) patients had CAD. The sensitivity and specificity of the presence of st-LGE to detect CAD were 69 and 92%, respectively. PLR and NLR were 8.47 and 0.33, respectively. In the meta-analysis, 1227 patients were included, and the prevalence of CAD ranged from 19.2 to 68.3%. Sensitivity, specificity, PLR and NLR were 87% (95% confidence interval [CI] 0.80–0.92), 93% (95% CI 0.89–0.96), 12.91 (95% CI 7.70–21.64) and 0.14 (95% CI 0.09–0.22), respectively. Altogether, 55 patients presented CAD with no st-LGE; inversely, 75 patients presented st-LGE with no CAD. Conclusion With a CMR specificity of 93%, the absence of st-LGE rules out significant underlying CAD in patients with systolic HF of unknown aetiology in most cases.
Published: 2018

35. Expression and Implication of Clusterin in Left Ventricular Remodeling After Myocardial Infarction

Author: Marie Fertin, Gilles Lemesle, Paul Mulder, Florence Pinet, Annie Turkieh, Sina Porouchani, Olivia Beseme, Nicolas Lamblin, Hervé Drobecq, Pascal de Groote, Philippe Amouyel, Christophe Bauters, Vincent Richard, Frédéric Mouquet, Maggy Chwastyniak, Marion Bouvet, Jean-Luc Balligand, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Endothélium, valvulopathies et insuffisance cardiaque (EnVI), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Mécanismes de la Tumorigénèse et Thérapies Ciblées - UMR 8161 (M3T), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université Catholique de Louvain = Catholic University of Louvain (UCL), and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)
Subjects: 0301 basic medicine, Adult, Male, Proteomics, medicine.medical_specialty, medicine.drug_class, Myocardial Infarction, Infarction, 030204 cardiovascular system & hematology, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Atrial natriuretic peptide, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Internal medicine, medicine, Natriuretic peptide, Extracellular, Humans, Myocardial infarction, Ventricular remodeling, Heart Failure, Clusterin, biology, Ventricular Remodeling, business.industry, Heart, medicine.disease, 3. Good health, 030104 developmental biology, Echocardiography, Heart failure, biology.protein, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Biomarkers
Abstract: Background: Left ventricular remodeling (LVR) after myocardial infarction is associated with an increased risk of heart failure and death. In spite of a modern therapeutic approach, LVR remains relatively frequent and difficult to predict in clinical practice. Our aim was to identify new biomarkers of LVR and understand their involvement in its development. Methods and Results: Proteomic analysis of plasma from the REVE-2 study (Remodelage Ventriculaire)—a study dedicated to the analysis of LVR which included 246 patients after a first anterior myocardial infarction—identified increased plasma levels of CLU (clusterin) in patients with high LVR. We used a rat model of myocardial infarction to analyze CLU expression in the LV and found a significant increase that was correlated with LVR parameters. We found increased CLU expression and secretion in primary cultures of rat neonate cardiomyocytes hypertrophied by isoproterenol. Silencing of CLU in hypertrophied neonate cardiomyocytes induced a significant decrease in cell size, ANP (atrial natriuretic peptide), and BNP (B-type natriuretic peptide) expression, associated with a decreased ERK (extracellular signal-regulated kinase) 1/2 activity, suggesting a prohypertrophic role of CLU. We then confirmed a significant increase of both intracellular p-CLU (precursor form of CLU) and m-CLU (mature form of CLU) in failing human hearts. Finally, the circulating levels of CLU (secreted form) were increased in patients with chronic heart failure who died from cardiovascular cause during a 3-year follow-up (n=99) compared with survivors (n=99). Conclusions: Our results show for the first time that plasma CLU levels are associated with LVR post–myocardial infarction, have in part a cardiac origin, and are a predictor of early death in heart failure patients.
Published: 2017

36. Factors associated with the 6-minute walk distance in patients with systemic sclerosis

Author: Jonathan Giovannelli, Hélène Maillard, Marc Lambert, Régis Matran, Sébastien Sanges, Céline Podevin, Thierry Perez, Eric Hachulla, Vincent Sobanski, David Launay, Pierre-Yves Hatron, Martine Remy-Jardin, Pascal de Groote, Jean-François Bervar, Sandrine Morell-Dubois, Nicolas Lamblin, Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Département de Médecine interne et d'Immunologie clinique [CHRU Lille], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre national de référence des maladies auto-immunes systémiques rares (sclérodermie systémique) [Lille], Service de cardiologie, Hôpital Cardiologique-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'explorations fonctionnelles respiratoires [Lille], CHU Lille, CNRS, Inserm, Université de Lille, Lille Inflammation Research International Center - U 995 [LIRIC], Lille Inflammation Research International Center (LIRIC) - U995, Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement (RID-AGE) - U1167, Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille], IMPact de l'Environnement Chimique sur la Santé humaine (IMPECS) - ULR 4483, METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694, Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 [RID-AGE], Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL], Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS], Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS], and Université de Lille, LillOA
Subjects: Male, lcsh:Diseases of the musculoskeletal system, 030204 cardiovascular system & hematology, Severity of Illness Index, Pulmonary function testing, Chronotropic incompetence, Systemic sclerosis, Exercise tolerance, Interstitial lung disease, Pulmonary hypertension, 6-minute walk test, MESH: Lung Diseases, Interstitial/etiology, MESH: Hypertension, Pulmonary/etiology, Disability Evaluation, 0302 clinical medicine, Heart Rate, MESH: Heart Rate, MESH: Aged, 2. Zero hunger, [SDV.MHEP.RSOA] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Middle Aged, MESH: Disability Evaluation, Middle Aged, 3. Good health, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Exercise Test/methods, Population study, Female, Research Article, Adult, medicine.medical_specialty, Hypertension, Pulmonary, Context (language use), 03 medical and health sciences, MESH: Cross-Sectional Studies, MESH: Severity of Illness Index, Internal medicine, medicine, Humans, Aged, MESH: Exercise Tolerance/physiology, 030203 arthritis & rheumatology, Scleroderma, Systemic, MESH: Humans, business.industry, MESH: Adult, medicine.disease, MESH: Male, Rheumatology, Cross-Sectional Studies, Exercise Test, MESH: Scleroderma, Systemic/complications, lcsh:RC925-935, Lung Diseases, Interstitial, business, MESH: Female, Body mass index, Rheumatism
Abstract: Background There is an ongoing debate regarding the relevance of the 6-minute walking distance (6MWD) in systemic sclerosis (SSc) assessment, widely used as a usual test in these patients as well as an outcome measure in clinical trials. In this work, we aimed to assess the associations between the 6MWD and various disease parameters in patients with SSc. Methods Consecutive patients followed in our SSc National Reference Centre were included in this cross-sectional study if they fulfilled the 2013 American College of Rheumatology/European League Against Rheumatism criteria for SSc. Data were systematically collected during a comprehensive standardized evaluation that included a 6-minute walk test, clinical assessment, biological results, pulmonary function tests, transthoracic echocardiography, composite scores (European Scleroderma Study Group Activity Index, Medsger severity score, Health Assessment Questionnaire–Disability Index (HAQ-DI)) and treatments. Associations of the 6MWD with various disease parameters were assessed by linear regression in univariate and multivariate analyses. Results The study population comprised 298 patients (females 81%; mean age 58.2 ± 13.3 years; limited cutaneous SSc 82%; interstitial lung disease (ILD) 42%; pulmonary arterial hypertension (PAH) 6%). The 6MWD was significantly and independently associated with gender, age, body mass index, baseline heart rate (HR), HR variation during the test, PAH, history of arterial thrombosis and C-reactive protein levels, as well as with the HAQ-DI score in a sensitivity analysis. Muscle involvement, joint involvement and ILD were not independently associated with the 6MWD. Conclusions During SSc, the 6MWD is independently associated with initial HR and HR variation; with PAH but not ILD, suggesting that pulmonary vasculopathy may have a greater impact than parenchymal involvement on functional limitation; and with global markers of disease activity and patient disability. These results give clinicians further insight into how to interpret the 6MWD in the context of SSc. Electronic supplementary material The online version of this article (doi:10.1186/s13075-017-1489-4) contains supplementary material, which is available to authorized users.
Published: 2017

37. Recurrent suspected myocarditis combined with infrahisian conduction disturbances revealing a desminopathy

Author: Pascale Richard, Stéphane Boulé, Philippe Charron, Pascal de Groote, and Florence Renaud
Subjects: medicine.medical_specialty, Myocarditis, Cardiomyopathy, medicine.medical_treatment, Case Report, Desmin, Internal medicine, medicine, Electrophysiologic study, Diseases of the circulatory (Cardiovascular) system, Purkinje, business.industry, Desminopathy, medicine.disease, Implantable cardioverter-defibrillator, ICD, implantable cardioverter-defibrillator, Pacemaker, RC666-701, Cardiology, Cardiology and Cardiovascular Medicine, business, Atrioventricular block, EPS, electrophysiologic study
Published: 2015
Full Text: View/download PDF

38. Diagnosis and treatment of iron deficiency in patients with heart failure: Expert position paper from French cardiologists

Author: Pascal de Groote, Richard Isnard, Alexandre Mebazaa, Christophe Leclercq, Michel Galinier, Alain Cohen-Solal, and Thibaud Damy
Subjects: medicine.medical_specialty, Ferritine sérique, medicine.medical_treatment, Transferrin saturation, Serum ferritin, Coefficient de saturation de la transferrine, Intravenous iron, Carence martiale, Quality of life, Internal medicine, medicine, Humans, Risk factor, Heart Failure, Heart transplantation, Ejection fraction, Anemia, Iron-Deficiency, business.industry, Iron deficiency, Disease Management, General Medicine, medicine.disease, Surgery, Insuffisance cardiaque, Clinical trial, Fer injectable, Heart failure, Practice Guidelines as Topic, France, Cardiology and Cardiovascular Medicine, business, Biomarkers
Abstract: SummaryThe prevalence of iron deficiency is high –even in the absence of anaemia– in patients with chronic heart failure (HF). Although iron deficiency is easily diagnosed with two biomarkers (serum ferritin and transferrin saturation), it is underdiagnosed in patients with HF. Iron is not only necessary for red blood cells, but also for cells in tissues with high-energy demands (heart, muscle, brain). Even before the onset of anaemia, HF patients with iron deficiency have decreased physical and cognitive performances and a poorer quality of life. Moreover, iron deficiency is a risk factor, independent of anaemia, of unfavourable outcome (death or heart transplantation) in patients with chronic HF. Several randomized controlled studies have shown improvement in exercise capacity, New York Heart Association functional class and quality of life after correction of iron deficiency. The results of these clinical trials, which are supported by European guidelines, suggest considering iron deficiency in HF as a possible therapeutic target.
Published: 2014

39. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

Author: Florence Parent, Xavier Jaïs, Athénaïs Boucly, Jason Weatherald, Emmanuel Bergot, Gérald Simonneau, Laurent Savale, C. Chabanne, François Picard, Arnaud Bourdin, David Montani, Vincent Cottin, Pascal de Groote, Ari Chaouat, Mitja Jevnikar, Grégoire Prévot, Olivier Sitbon, Marc Humbert, Université Paris-Sud - Paris 11 - Faculté de médecine (UP11 UFR Médecine), Université Paris-Sud - Paris 11 (UP11), Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre chirurgical Marie Lannelongue, Centre de Référence des Maladies Pulmonaires Rares [Hôpital Louis Pradel - HCL], Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de pneumologie [Toulouse], CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Département de cardiologie, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Interactions Gènes-Risques environnementaux et Effets sur la Santé (INGRES), Université de Lorraine (UL), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Universiteacute, Paris-Sud, Agence Nationale de la Recherche, Centre Chirurgical Marie Lannelongue (CCML)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), and Centre chirurgical Marie Lannelongue-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, Hypertension, Pulmonary, Atrial Pressure, Walk Test, Risk management tools, 030204 cardiovascular system & hematology, World Health Organization, Risk Assessment, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, Natriuretic Peptide, Brain, medicine, Lung transplantation, Humans, Pulmonary Vascular Diseases, Familial Primary Pulmonary Hypertension, Registries, Survival analysis, ComputingMilieux_MISCELLANEOUS, Aged, Retrospective Studies, business.industry, Central venous pressure, Retrospective cohort study, Original Articles, Middle Aged, Prognosis, Survival Analysis, 3. Good health, 030228 respiratory system, Multivariate Analysis, Practice Guidelines as Topic, Physical therapy, Female, France, business, Risk assessment, Biomarkers, Lung Transplantation
Abstract: Current European guidelines recommend periodic risk assessment for patients with pulmonary arterial hypertension (PAH). The aim of our study was to determine the association between the number of low-risk criteria achieved within 1 year of diagnosis and long-term prognosis. Incident patients with idiopathic, heritable and drug-induced PAH between 2006 and 2016 were analysed. The number of low-risk criteria present at diagnosis and at first re-evaluation were assessed: World Health Organization (WHO)/New York Heart Association (NYHA) functional class I or II, 6-min walking distance (6MWD) >440 m, right atrial pressure, Simplified risk assessment using the number of low-risk criteria predicts prognosis at baseline and follow-up in PAH http://ow.ly/KMsj30cPNbm
Published: 2017

40. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)

Author: Manuel Gómez-Bueno, Pascal De Groote, Albert HAGEGE, Aldo Pietro Maggioni, Laila Hübbert, Tchavdar Shalganov, Michel GALINIER, Katarzyna Mizia-Stec, Dirk Westermann, Burkert Pieske, Jiří Knot, Michael Zile, Piotr Ponikowski, John Atherton, Vojtech Melenovsky, University of Zurich, and Gheorghiade, Mihai
Subjects: Male, medicine.medical_specialty, Administration, Oral, Receptors, Cytoplasmic and Nuclear, 610 Medicine & health, Placebo, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, chemistry.chemical_compound, Soluble Guanylyl Cyclase, Double-Blind Method, Pharmacokinetics, Internal medicine, Natriuretic Peptide, Brain, medicine, Clinical endpoint, Heart Failure/blood, Humans, Protein Precursors, Cyclic guanosine monophosphate, Aged, Heart Failure, Ejection fraction, business.industry, Stroke Volume, Prognosis, medicine.disease, Peptide Fragments, Guanylate Cyclase/administration & dosage, Treatment Outcome, Tolerability, chemistry, Stroke Volume/physiology, Guanylate Cyclase, Heart failure, Pharmacodynamics, Anesthesia, Cardiology, Female, Natriuretic Peptide, Brain/blood, Peptide Fragments/blood, Cardiology and Cardiovascular Medicine, business, Receptors, Cytoplasmic and Nuclear/administration & dosage
Abstract: Aims The clinical outcomes for patients with worsening chronic heart failure (WCHF) remain exceedingly poor despite contemporary evidence-based therapies, and effective therapies are urgently needed. Accumulating evidence supports augmentation of cyclic guanosine monophosphate (cGMP) signalling as a potential therapeutic strategy for HF with reduced or preserved ejection fraction (HFrEF and HFpEF, respectively). Direct soluble guanylate cyclase (sGC) stimulators target reduced cGMP generation due to insufficient sGC stimulation and represent a promising method for cGMP enhancement. Methods The phase II SOluble guanylate Cyclase stimulatoR in heArT failurE Study (SOCRATES) programme consists of two randomized, parallel-group, placebo-controlled, double-blind, multicentre studies, SOCRATES-REDUCED (in patients with LVEF
Published: 2014

41. Long-Term Functional and Clinical Follow-Up of Patients With Heart Failure With Recovered Left Ventricular Ejection Fraction After β-Blocker Therapy

Author: Pascal de Groote, Nicolas Lamblin, Anju Duva Pentiah, Céline Goéminne, Christophe Bauters, and Marie Fertin
Subjects: Adult, Male, medicine.medical_specialty, Time Factors, Systole, Adrenergic beta-Antagonists, Comorbidity, Ventricular Dysfunction, Left, Risk Factors, Internal medicine, Heart rate, medicine, Humans, Longitudinal Studies, cardiovascular diseases, Aged, Heart Failure, Ejection fraction, business.industry, Stroke Volume, Middle Aged, Prognosis, medicine.disease, Survival Rate, Treatment Outcome, Echocardiography, Heart failure, cardiovascular system, Cardiology, Population study, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract: Background— Some patients with left ventricular systolic dysfunction (LVSD) have a dramatic improvement in left ventricular ejection fraction (LVEF) after β-blockade. No study has analyzed the long-term echocardiographic and clinical follow-up of this subgroup of patients. Methods and Results— We included in this analysis 174 consecutive patients with LVSD who had an LVEF≥45% after β-blockade. We performed a long-term echocardiographic follow-up (median 7.7 [4–9.9] years) and clinical follow-up (median 9.2 [7.2–10.8] years). LVEF improved from 33±8% to 54±6% after β-blockade ( P Conclusions— The long-term survival of patients with LVSD and with near-normal LVEF after β-blockade is good. However, a quarter of these patients may experience a subsequent degradation of LVEF. These patients are at higher risk of cardiovascular mortality.
Published: 2014

42. 1- and 5-year outcomes of heart failure patients with reduced and preserved ejection fraction after acute decompensation according to the final destination after emergency department care

Author: O Raitiere, Pascal de Groote, Erwan Donal, Richard Isnard, Damien Logeart, Jean-Christophe Eicher, Guillaume Jondeau, Marie-France Seronde, Jean-Noël Trochu, Yves Juillière, Fabrice Bauer, P. Jourdain, Thibaud Damy, P Guignant, and Michel Galinier
Subjects: Geriatrics, medicine.medical_specialty, Ejection fraction, business.industry, Hazard ratio, Mean age, Emergency department, medicine.disease, Primary outcome, Heart failure, Emergency medicine, Medicine, Decompensation, Cardiology and Cardiovascular Medicine, business
Abstract: Background Outcome of acute heart failure (AHF) patients according to the final destination after emergency department (ED) has been poorly studied with contradictory results. Purpose To compare long-term outcomes after an episode of acute heart failure (AHF) in patients according to their destinations after ED. Methods OFICA (Observatoire Francais de l’Insuffisance Cardiaque Aigue) is a French snapshot registry of all patients with ongoing hospitalization for AHF in a nationwide and representative sample of 170 French hospitals. One thousand six hundreds and fifty-seven patients were included the 12th of March, 2009. Various data were collected including the final destination after ED and patients were followed-up for death as primary outcome. Hazard ratios were calculated for patients admitted in geriatric departments and other wards then compared with those hospitalized in cardiology. P Results Mean age was 76,0 ± 13,2 y with a sex-ratio close to 1. Overall, the small number of AHF patients referred from the ED to a cardiology ward was 19% with more frequently HF REF. Besides, AHF patients admitted in geriatric unit were older (p Conclusion While patients have similar 1-year outcomes irrespective of the destination after ED care for an AHF episode, those initially admitted in geriatrics present worse 5-year outcomes when managed by non-cardiology departments, despite adjustment for different clinical patient profiles. Reasons for this heterogeneous specialty-related performance should be investigated.
Published: 2019

43. Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients

Author: Sophie Garnier, Laurent Fauchier, Ulrike Esslinger, Philippe Charron, Benjamin Meder, Karen S. Frese, Eric Villard, Richard Isnard, Christian Hengstenberg, Olivier Dubourg, Hugo A. Katus, Eloisa Arbustini, Nicolas Lamblin, Michel Komajda, Pascal de Groote, Jean Noel Trochu, Stuart A. Cook, Paul J.R. Barton, Laurence Tiret, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Department of Internal Medicine II, Division of Respirology, University of Regensburg, Regensburg, Germany, Universität Regensburg (UR), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), IRCCS - Pavia, Royal Brompton and Harefield NHS Foundation Trust, Heidelberg University Hospital [Heidelberg], Université Pierre et Marie Curie - Paris 6 (UPMC), Duke-NUS Medical School [Singapore], National Heart and Lung Institute, Imperial College London, National Heart Centre Singapore (NHCS), British Heart Foundation, Administateur, HAL Sorbonne Université, Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Cardiac output, Cardiac & Cardiovascular Systems, Internationality, HSP27 Heat-Shock Proteins, Dilated cardiomyopathy, Disease, 030204 cardiovascular system & hematology, Cohort Studies, 0302 clinical medicine, Germany, Aged, 80 and over, 0303 health sciences, Ejection fraction, Incidence, ASSOCIATION, Middle Aged, Prognosis, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, 3. Good health, Europe, Italy, Cardiology, Female, France, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, Cardiomyopathy, Dilated, medicine.medical_specialty, Genotype, PROTEINS, Risk Assessment, 1102 Cardiovascular Medicine And Haematology, 03 medical and health sciences, Age Distribution, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Idiopathic dilated cardiomyopathy, Genetics, medicine, Humans, Sex Distribution, Ischemic heart failure, Adaptor Proteins, Signal Transducing, Aged, Association studies, 030304 developmental biology, Science & Technology, business.industry, Case-control study, medicine.disease, Survival Analysis, Gene Expression Regulation, Cardiovascular System & Hematology, Genetic Loci, Case-Control Studies, Heart failure, Cardiovascular System & Cardiology, Etiology, Apoptosis Regulatory Proteins, business, Genome-Wide Association Study, Heart Failure, Systolic
Abstract: International audience; Heart failure (HF), a major public health burden affecting 2% of industrialized populations, is a syndrome resulting from structural or functional myocardial impairment leading to inadequate cardiac output to meet the body's metabolic demands [1]. Half of HF patients present systolic dysfunction (systolic-HF), also called reduced ejection fraction (HF-REF), a disease related to various causes including idiopathic Dilated Cardiomyopathy (DCM) and Coronary Artery Diseases (CAD) (ischemic-HF). HF is usually a multifactorial disease but the genetic variants contributing to its susceptibility or its severity may be different according to its underlying causes [2] and their identification is only beginning.[...]
Published: 2015

44. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study

Author: Damien, Logeart, Richard, Isnard, Matthieu, Resche-Rigon, Marie-France, Seronde, Pascal, de Groote, Guillaume, Jondeau, Michel, Galinier, Geneviève, Mulak, Erwan, Donal, François, Delahaye, Yves, Juilliere, Thibaud, Damy, Patrick, Jourdain, Fabrice, Bauer, Jean-Christophe, Eicher, Yannick, Neuder, Jean-Noël, Trochu, Yaici, Khelil, Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique, pharmacologie et physiopathologie des maladies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de cardiologie, Hôpital Cardiologique-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hémostase, bio-ingénierie et remodelage cardiovasculaires (LBPC), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut Galilée-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie (Hôpital Louis Pradel), Hospices Civils de Lyon (HCL), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CIC - CHU Henri Mondor, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Cardiologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Radiopharmaceutiques biocliniques, Université Joseph Fourier - Grenoble 1 (UJF)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Heart Failure of the French Society of Cardiology, Biomarqueurs CArdioNeuroVASCulaires ( BioCANVAS ), Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( PCVP / CARDIO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Hôpital Cardiologique-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Hémostase, bio-ingénierie et remodelage cardiovasculaires ( LBPC ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Galilée, Department of Cardiology, Université Paul Sabatier - Toulouse 3 ( UPS ) -CHU Toulouse [Toulouse], Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Services de Pneumologie, Exploration Fonctionnelle Respiratoire et Cardiologie ( Hôpital Louis Pradel ), Hospices Civils de Lyon ( HCL ), Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), unité de recherche de l'institut du thorax UMR1087 UMR6291 ( ITX ), Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Université Paris Diderot - Paris 7 (UPD7)-Université Paris 13 (UP13)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Galilée, Service de cardiologie [Toulouse], Hôpital de Rangueil, CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, MESH: Registries, Hospital mortality, Cross-sectional study, MESH : Aged, [ SPI.SIGNAL ] Engineering Sciences [physics]/Signal and Image processing, MESH: Hospitalization, 030204 cardiovascular system & hematology, Severity of Illness Index, Medical Records, MESH : Cross-Sectional Studies, MESH: Aged, 80 and over, 0302 clinical medicine, [INFO.INFO-TS]Computer Science [cs]/Signal and Image Processing, Epidemiology, MESH : Female, Registries, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, 030212 general & internal medicine, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Ejection fraction, Medical record, MESH : Acute Disease, Middle Aged, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Health survey, 3. Good health, Hospitalization, Treatment Outcome, Acute Disease, MESH : Hospitalization, MESH: Acute Disease, Female, MESH : Severity of Illness Index, [SDV.IB]Life Sciences [q-bio]/Bioengineering, France, Cardiology and Cardiovascular Medicine, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, MESH: Medical Records, medicine.medical_specialty, [ INFO.INFO-TS ] Computer Science [cs]/Signal and Image Processing, MESH : Male, Heart failure, MESH : Treatment Outcome, Therapeutics, Guidelines, MESH : Hospital Mortality, 03 medical and health sciences, MESH: Cross-Sectional Studies, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH: Severity of Illness Index, Internal medicine, MESH : Medical Records, Severity of illness, medicine, Humans, MESH : Middle Aged, MESH: Hospital Mortality, MESH : Aged, 80 and over, MESH : France, Intensive care medicine, Aged, MESH: Humans, Aldosterone inhibitor, business.industry, MESH : Humans, medicine.disease, MESH: Male, MESH: France, Cross-Sectional Studies, Blood pressure, MESH: Heart Failure, MESH : Heart Failure, business, MESH: Female, MESH : Registries
Abstract: International audience; AIMS: To improve knowledge of epidemiological data, management, and clinical outcome of acute heart failure (AHF) in a real-life setting in France. METHODS AND RESULTS: We conducted an observational survey constituting a single-day snapshot of all unplanned hospitalizations because of AHF in 170 hospitals throughout France (the OFICA survey). A total of 1658 patients (median age 79 years, 55% male) were included. Family doctors were the first medical contact in 43% of cases, and patients were admitted through emergency departments in 64% of cases. Clinical scenarios were mainly acutely decompensated HF (48%) and acute pulmonary oedema (38%) with similar clinical and biological characteristics as well as outcome. Characteristics were different and severity higher in both shock and right HF. Infection and arrhythmia were the most frequent precipitating factors (27% and 24% of cases); diabetes and chronic pulmonary disease were the most frequent co-morbidities (31% and 21%). Over 80% of patients underwent both natriuretic peptide testing and echocardiography. LVEF was preserved (>50%) in 36% of patients and associated with specific characteristics and lower severity. Median hospital stay was 13 days; in-hospital mortality was 8.2%, and independent predictors were age, blood pressure, and creatinine. Treatment at discharge in patients with reduced LVEF included ACE inhibitors/ARBs, beta-blockers, and aldosterone inhibitors in 78, 67, and 27% cases. Non-surgical devices were reported in
Published: 2013

45. New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure

Author: Pascal de Groote, Ariel Cohen, Thibaud Damy, and Yves Juillière
Subjects: medicine.medical_specialty, Cardiology, 030204 cardiovascular system & hematology, Ventricular Function, Left, Cardiac Resynchronization Therapy, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Terminology as Topic, medicine, Humans, 030212 general & internal medicine, Practice Patterns, Physicians', Intensive care medicine, Heart Failure, Evidence-Based Medicine, business.industry, Interpretation (philosophy), Cardiovascular Agents, Stroke Volume, General Medicine, medicine.disease, Prognosis, Europe, Heart failure, Chronic Disease, Practice Guidelines as Topic, Diffusion of Innovation, Cardiology and Cardiovascular Medicine, business, Algorithms
Published: 2016

46. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases

Author: Michel Komajda, Giuseppe Limongelli, James C. Moon, Stephane Heymans, Eloisa Arbustini, Perry M. Elliott, Petar M. Seferovic, Yigal M. Pinto, Aristides Anastasakis, Alida L.P. Caforio, Yehuda Adler, Petronella G. Pieper, José Luis Zamorano, Massimo Imazio, Karin Klingel, Pascal de Groote, Jens Mogensen, Michael Böhm, P. Charron, Aleš Linhart, Stephan Schueler, Juan R. Gimeno, Denis Duboc, Cardiovascular Centre (CVC), Pinto, Yigal M., Elliott, Perry M., Arbustini, Eloisa, Adler, Yehuda, Anastasakis, Ari, Bã¶hm, Michael, Duboc, Deni, Gimeno, Juan, De Groote, Pascal, Imazio, Massimo, Heymans, Stephane, Klingel, Karin, Komajda, Michel, Limongelli, Giuseppe, Linhart, Ale, Mogensen, Jen, Moon, Jame, Pieper, Petronella G., Seferovic, Petar M., Schueler, Stephan, Zamorano, Jose L., Caforio, Alida L. P., Charron, Philippe, ACS - Amsterdam Cardiovascular Sciences, Cardiology, Cardiologie, RS: CARIM - R2.02 - Cardiomyopathy, and MUMC+: MA Med Staf Spec Cardiologie (9)
Subjects: Cardiomyopathy, Dilated, medicine.medical_specialty, Myocarditis, Peripartum cardiomyopathy, Cardiomyopathy, Dilated cardiomyopathy, RELATIVES, Heart failure, Position statement, 030204 cardiovascular system & hematology, Gene mutation, DIAGNOSIS, Multimodal Imaging, LAMIN A/C MUTATION, Diagnosis, Differential, Cardiomyopathies/diagnosis, 03 medical and health sciences, 0302 clinical medicine, PERIPARTUM CARDIOMYOPATHY, Risk Factors, Internal medicine, medicine, MANAGEMENT, Humans, Clinical significance, 030212 general & internal medicine, RISK, HEART-FAILURE ASSOCIATION, business.industry, Dilated cardiomyopathy Position statement Heart failure lamin a/c mutation heart-failure association european-society peripartum cardiomyopathy muscular-dystrophy gene-mutations risk diagnosis management relatives Cardiovascular System & Cardiology, medicine.disease, EUROPEAN-SOCIETY, MUSCULAR-DYSTROPHY, Pedigree, Early Diagnosis, Cardiomyopathy, Dilated/diagnosis, Cardiology, Differential diagnosis, Cardiology and Cardiovascular Medicine, business, Cardiomyopathies, Myocarditis/diagnosis, Multimodal Imaging/methods, GENE-MUTATIONS
Abstract: In this paper the Working Group on Myocardial and Pericardial Disease proposes a revised definition of dilated cardiomyopathy (DCM) in an attempt to bridge the gap between our recent understanding of the disease spectrum and its clinical presentation in relatives, which is key for early diagnosis and the institution of potential preventative measures. We also provide practical hints to identify subsets of the DCM syndrome where aetiology directed management has great clinical relevance.
Published: 2016

47. Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction

Author: Sebastian Preissl, Florence Pinet, Karina Zimmer, Pascal de Groote, Shashi Kumar Gupta, Sabrina Thum, Thomas Thum, Leon J. De Windt, Christophe Bauters, Reinier A. Boon, Janet Remke, Lutz Hein, Ariana Foinquinos, Sandor Batkai, Hannover Medical School [Hannover] (MHH), Epidémiologie des maladies chroniques: impact des intéractions gène environnement sur la santé des populations, Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hubrecht Laboratory and Interuniversity Cardiology Institute, Utrecht University [Utrecht], Institute for Molecular and Translational Therapeutic Strategies - IMTTS [Hannover, Germany], Facteurs de Risque et Déterminants Moléculaires des Maladies liées au Vieillissement - U 1167 (RID-AGE), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute of Molecular and Translational Therapeutic Strategies (IMTTS), RS: CARIM - R2.07 - Gene regulation, Cardiologie, Physiology, and ICaR - Ischemia and repair
Subjects: 0301 basic medicine, Cardiac function curve, Myocardial Infarction, MiR-22, 030204 cardiovascular system & hematology, Muscle hypertrophy, 03 medical and health sciences, Mice, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, microRNA, Autophagy, Medicine, Animals, Humans, Myocytes, Cardiac, Myocardial infarction, ComputingMilieux_MISCELLANEOUS, Cells, Cultured, Aged, Heart Failure, business.industry, aging, p62, Transfection, medicine.disease, 3. Good health, circulating miRNA, Disease Models, Animal, MicroRNAs, 030104 developmental biology, Editorial, Heart failure, Immunology, Cancer research, Biomarker (medicine), Cardiology and Cardiovascular Medicine, business, Biomarkers
Abstract: BACKGROUND: Aging populations show higher incidences of myocardial infarction (MI) and heart failure (HF). Cardiac remodeling post-MI leads to progressive impaired cardiac function caused by a disarray of several processes including derailed autophagy. Microribonucleic acids (miRNAs) are known to be key players in cardiovascular disease but their involvement in cardiac autophagy and aging is not well understood.OBJECTIVES: This study sought to identify new miRNA candidates that regulate cardiac autophagy and aging.METHODS: We exploited a high-throughput, fluorescence-activated cell sorting-based green fluorescent protein-LC3 detection method to measure the autophagic flux in cardiomyocytes after transfection of a precursor miRNA library consisting of 380 miRNAs. This was followed by a series of molecular and in vivo studies.RESULTS: Together with additional expression screenings, we identified miR-22 as an abundant and strong inhibitor of the cardiac autophagy process. Cardiac miR-22 expression levels increased during aging of mice as well as in aging neonatal cardiomyocytes in vitro by a P53-dependent mechanism. Inhibition of miR-22 in aging cardiomyocytes in vitro activated autophagy and inhibited cellular hypertrophy. Pharmacological inhibition of miR-22 post-MI in older mice activated cardiac autophagy, prevented post-infarction remodeling, and improved cardiac function compared with control subjects. Interestingly, similar effects were less pronounced in younger mice with significantly lower cardiac miR-22 expression levels. In addition, circulating levels of miR-22 in 154 patients with systolic HF were highly associated with early mortality.CONCLUSIONS: We concluded that miR-22 is an important regulator of cardiac autophagy and a potential therapeutic target, especially in the older myocardium. Finally, circulating miR-22 provides prognostic information for HF patients, highlighting miR-22 as a promising therapeutic and biomarker candidate for cardiovascular disorders.
Published: 2016

48. Initial dual oral combination therapy in pulmonary arterial hypertension

Author: Pascal de Groote, Céline Chabannes, Laurent Savale, Laurent Bertoletti, Emmanuel Bergot, Olivier Sitbon, Claire Dauphin, Fabrice Bauer, Xavier Jaïs, Gérald Simonneau, Hélène Bouvaist, Ari Chaouat, Marc Humbert, Caroline Sattler, Arnaud Bourdin, David Montani, Vincent Cottin, Service de Pneumologie et Réanimation Respiratoire (DHU TORINO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre-Centre de Référence de l'Hypertension Pulmonaire Sévère, Université Paris-Sud - Paris 11 (UP11), Hypertension arterielle pulmonaire physiopathologie et innovation thérapeutique, Centre chirurgical Marie Lannelongue-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Saint Etienne, Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de recherche sur la thrombose (GRT (EA 3065)), Université Jean Monnet [Saint-Étienne] (UJM), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service de Pneumologie, Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Interactions Gènes-Risques environnementaux et Effets sur la Santé (INGRES), Université de Lorraine (UL), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pneumologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Cardiologie, CHU Grenoble, CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Service de cardiologie [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Actelion Pharmaceuticals, Département Hospitalo-Universitaire Thorax Innovation, Laboratoire d’Excellence en Recherche sur le Médicament et l’Innovation Thérapeutique, Centre Chirurgical Marie Lannelongue (CCML)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Jean Monnet - Saint-Étienne (UJM), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent, Centre d'Investigation Clinique - Epidémiologie Clinique Saint-Etienne (CIC-EC), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E)-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Groupe de recherche sur la thrombose, pharmacologie des antithrombotiques et situations à risque (GRT)
Subjects: Male, Time Factors, 030204 cardiovascular system & hematology, Gastroenterology, Severity of Illness Index, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Tadalafil, chemistry.chemical_compound, 0302 clinical medicine, Familial Primary Pulmonary Hypertension, Sulfonamides, Phenylpropionates, Middle Aged, 3. Good health, Pyridazines, Treatment Outcome, [SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, Diethylpropion, Drug Therapy, Combination, Female, Patient Safety, medicine.drug, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, Ambrisentan, Combination therapy, Sildenafil, Hypertension, Pulmonary, Sildenafil Citrate, 03 medical and health sciences, Pharmacotherapy, Internal medicine, Severity of illness, medicine, Humans, Antihypertensive Agents, Aged, Retrospective Studies, business.industry, Hemodynamics, Bosentan, Surgery, 030228 respiratory system, chemistry, Concomitant, [SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, business, Follow-Up Studies
Abstract: Treatment for pulmonary arterial hypertension (PAH) has been underpinned by single-agent therapy to which concomitant drugs are added sequentially when pre-defined treatment goals are not met.This retrospective analysis of real-world clinical data in 97 patients with newly diagnosed PAH (86% in New York Heart Association functional class III−IV) explored initial dual oral combination treatment with bosentan plus sildenafil (n=61), bosentan plus tadalafil (n=17), ambrisentan plus tadalafil (n=11) or ambrisentan plus sildenafil (n=8).All regimens were associated with significant improvements in functional class, exercise capacity, dyspnoea and haemodynamic indices after 4 months of therapy. Over a median follow-up period of 30 months, 75 (82%) patients were still alive, 53 (71%) of whom received only dual oral combination therapy. Overall survival rates were 97%, 94% and 83% at 1, 2 and 3 years, respectively, and 96%, 94% and 84%, respectively, for the patients with idiopathic PAH, heritable PAH and anorexigen-induced PAH. Expected survival rates calculated from the French equation for the latter were 86%, 75% and 66% at 1, 2 and 3 years, respectively.Initial combination of oral PAH-targeted medications may offer clinical benefits, especially in PAH patients with severe haemodynamic impairment.
Published: 2016

49. Unexpected and rapid recovery of left ventricular function in patients with peripartum cardiomyopathy: impact of cardiac resynchronization therapy

Author: Nicolas Lamblin, Christelle Marquié, Pascal de Groote, Capucine Coulon, Meriem Mostefa Kara, Frédéric Mouquet, and Stephane Langlois
Subjects: Cardiomyopathy, Dilated, Cardiac function curve, medicine.medical_specialty, Peripartum cardiomyopathy, medicine.medical_treatment, Pregnancy Complications, Cardiovascular, Cardiac resynchronization therapy, Cardiomyopathy, Ventricular Function, Left, Cardiac Resynchronization Therapy, Pregnancy, Internal medicine, Peripartum Period, Ventricular Dysfunction, medicine, Humans, Prospective Studies, Prospective cohort study, Ventricular Remodeling, business.industry, Dilated cardiomyopathy, Puerperal Disorders, medicine.disease, Defibrillators, Implantable, Treatment Outcome, Heart failure, Cardiology, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract: Aim Peripartum cardiomyopathy (PPCM) is a rare cause of dilated cardiomyopathy responsible for heart failure toward the end of pregnancy, which can lead to chronic heart failure in 50% of cases. In this short report, we assessed the benefit of cardiac resynchronization in patients with PPCM and chronic systolic dysfunction despite optimal medical treatment. Methods and results For the last 10 years, we managed eight patients diagnosed with PPCM. Two of them presented severe systolic dysfunction, and medical treatment resulted in limited improvement from 10% to 25% and from 25% to 28% despite optimal treatment for 9 and 6 years, respectively. These two patients were porposed to receive an implantatable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT). Six months after ICD-CRT treatment, we observed a significant improvement in systolic function from 25% to 45% and 28% to 50%, respectively, and positive remodelling with reduction of left ventricular end-diastolic volume from 216 to 144 mL and from 354 to 105 mL, which represent a 34% and a 70% reduction, respectively. Conclusions Physicians in charge of patients with PPCM should offer the opportunity of CRT for patients whose cardiac function has not significantly improved under standard medical treatment.
Published: 2012

50. Subacute right heart failure revealing three simultaneous causes of post-embolic pulmonary hypertension in metastatic dissemination of breast cancer

Author: Flavien, Vincent, Nicolas, Lamblin, Marion, Classe, Guillaume, Schurtz, Antoine, Rauch, Marie, Fertin, and Pascal, De Groote
Subjects: Death, Dyspnea, Pulmonary embolism, cardiovascular system, Tumor cell embolic, Case Report, Case Reports, Right heart failure, Carcinomatosis lymphangitis, Pulmonary tumor thrombotic microangiopathy, Cardiogenic shock, Pulmonary hypertension
Abstract: A 72‐year‐old woman with history of breast cancer only treated surgically was referred to our department for pulmonary hypertension (PH) suspicion. Echocardiogram revealed elevated right ventricular systolic pressure. Computed tomography (CT) angiogram showed no pulmonary embolism (PE), but lung scan revealed two ventilation‐perfusion mismatch areas. Right cardiac catheterization established precapillary PH. Despite treatment with PH specific therapy (sildenafil, ambrisentan, and epoprostenol), her condition worsened rapidly with acute right heart failure (RHF). She died 22 days after admission. Post‐mortem microscopic examination showed a rare combination of PH etiologies consistent with metastasis of breast cancer in pulmonary vasculature including the rare pulmonary tumour thrombotic microangiopathy (PTTM).
Published: 2015

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Database

Publisher

108 results on '"Pascal de Groote"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources